{"title": "PDF", "author": "PDF", "url": "https://www.leitlinien.de/themen/diabetes/archiv/pdf/therapie-des-typ-2-diabetes/dm-therapie-1aufl-vers1-evidenztabellen.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung. \n \nProgramm f\u00fcr Nationale VersorgungsLeitlinien \nTr\u00e4ger:  \nBundes\u00e4rztekammer  \nKassen\u00e4rztliche Bundesvereinigung \nArbeitsgemeinschaft der Wissenschaftlichen  \nMedizinischen Fachgesellschaften \nNationale VersorgungsLeitlinie \nTherapie \ndes Typ-2-Diabetes \nEvidenztabellen \n1. Auflage \nVersion 1 \nJanuar 2014 \nAWMF-Register:Nr.: nvl-001g \nErg\u00e4nzungen und Modifikationen der Leitlinie sind \u00fcber \ndie Webseite http://www.diabetes.versorgungsleitlinien.de  zug\u00e4nglich. \nWichtiger Hinweis: \nBitte beachten Sie, dass nur die unter http://www.versorgungsleitlinien.de  enthaltenen Dokumente des \nProgramms f\u00fcr Nationale VersorgungsLeitlinien du rch die Tr\u00e4ger des NVL-Programms autorisiert und \ndamit g\u00fcltig sind. Bei NVL-Dokumenten, die Sie von anderen Webseiten beziehen, \u00fcbernehmen wir \nkeine Verantwortung f\u00fcr deren G\u00fcltigkeit.  \n\u00a9 \nG\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  2 \nInhaltsverzeichnis \n1\u00a0 Evidenztabellen Kapitel 6 Pharmakotherapie 3\u00a0\n2\u00a0 Evidenztabelle HbA1c-Senkung (und weitere Endpunkte) 56\u00a0\n3\u00a0 Abk\u00fcrzungsverzeichnis 64 \u00a0\n4\u00a0 Literatur aus systematischen Review von Esposito et al. (2012) [7] 65 \u00a0\n5\u00a0 Literatur 74 \u00a0\n \n G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4           3  \n1 Evidenztabellen Kapitel 6 Pharmakotherapie  \nSystematischer Review, Metaanalyse, HTA \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nNetwork \nMeta-\nAnalysis, \nSystema-\ntischer \nReview Gross JL et \nal. (2011) \n[1]  databases:  \nMEDLINE, EM-\nBASE, Cochrane \nLibrary, LILACS, \nand Clinical-\nTrials.gov elec-\ntronic databases \n+ manual search \n+ unpublished \ndata (one) \ninclusion and \nexclusion criteria:  \nRandomized trials \nat least 24 weeks \nin duration. Stu-\ndies evaluated the \neffects of adding \na third antihyper-\nglycemic drug to \ntreatment of \nadults aged 18 \nyears or older \nwith type 2 \ndiabetes and a \nhemoglobin A1c  \n(HbA1c) level \ngreater than 7.0% \nwho were already \nreceiving a com-\nbination of 1)combination of \nmetformin and a sul-\nfonylurea  +  a third non-\ninsulin antihypergly-\ncemic drug  \nversus   \nplacebo as third drug \n2) combination of \nmetformin and a sul-\nfonylurea  +  a third non-\ninsulin anti-\nhyperglycemic drug \nversus   \ninsulin as third drug \n(Options for third agents \ninclude insulin, -\nglucosidase inhibitors \n(acarbose), thiazolidine-\ndiones, glucagon-like \npeptide-1 (GLP-1) \nagonists, and dipeptidyl \npeptidase-4 inhibitors) Primary end points: \nchange in HbA1c \nchange in weight \nfrequency of severe hypoglycemia. \nResults:  \nEighteen trials involving 4535 participants \nthat lasted a mean of 31.3 weeks (24 to \n52 weeks) were included.  \nmean baseline HbA1c level of 8.8% (7.5% \nto 10.6%), a mean baseline BMI of 28.8 \nkg/m2 (24.0 kg/m2 to 34.2 kg/m2), and \ndiabetes duration of 8.9 years (8.1 to 13.6 \nyears). \nNine studies reported adequate randomi-\nzation, 0 were stopped early, and 15 did \nnot specify whether data collectors and \noutcome assessors were blinded to study \ndata. \nThere was no evidence of publication bias \nwhen HbA1c level was used as an out-\ncome.  \nResults in detail for direct and indirect \ncomparisons: see table 2+3 below methodological weaknesses \nand strenght: \nMost of the trials were short \nterm, and trial quality varied. \nWith so few trials relative to \nantihyperglycemic agents, \ninvestigators relied on indirect \ncomparisons, which increased \nthe uncertainty of the findings \nand conclusions. \nThe quality of trial conduct \nand reporting varied;  only 5 of \n18 studies included in the \nanalyses were double-blind, \nand details of allocation were \nnoted in only 9 of 18 studies, \nsuggesting that other  poten-\ntial biases may have been \nintroduced. Treatment regi-\nmens and patient populations \nvaried \nThey did a conventional meta-\nanalysis, but because the \nnumber of randomized trials \ndirectly comparing antihyper-\nglycemic agents was limited, \nthey also used indirect com-\nparisons and network meta-\nanalysis with Bayesian soft-\nware WinBUGS. 16. Lam KS et al, \nDiabetes Care. 1998; \n17. Ko GT, Tsang CC, \nNg CW, Wai HP, Kan \nEC. Clin Drug Investig. \n2001; \n18. Yale JF et al, Ann \nIntern Med. 2001; \n19. Dailey GE et al. Am \nJ Med. 2004; \n20. Heine RJ, Van Gaal \nLF, Johns D, Mihm MJ, \nWidel MH, Brodows \nRG;Ann Intern Med. \n2005; \n21. Kendall DM et al. \nDiabetes Care. 2005; \n22. Ko GT, Tsang PC, \nWai HP, Kan EC, Chan \nHC. Adv Ther. 2006; \n23. Rosenstock J, \nSugimoto D, Strange P, \nStewart JA, Soltes-Rak \nE, Dailey G. Diabetes \nCare. 2006; \n24. Hermansen K, \nKipnes M, Luo E, Fa-\nnurik D, Khatami H, \nStein P; Diabetes Obes 1+ G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4           4  \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nmetformin and a \nsulfonylurea for at \nleast 3 months.  \nAt least 24 weeks \nof follow-up, and \nreported changes \nin HbA1c level \nand weight and \nnumbers of pa-\ntients with severe \nhypoglycemic \nreactions as \ndefined by the \ninvestigator or as \nreactions requi-\nring third-party \nassistance or \nblood glucose \nlevels of 1.9 \nmmol/L (35 \nmg/dL) or less. \nExclusion: \nStudies compa-\nring 2 formula-\ntions of insulins \nas a third agent in \nboth groups were \nexcluded. \nsearch period: \nFrom 1950 to \nDecember 2010 \nby using the \nMedical Subject \nHeading terms Two independent investiga-\ntors reviewed study titles and \nabstracts. Trials selected for \ndetailed analysis and data \nextraction were analyzed by 2 \ninvestigators with an agree-\nment value Kappa of 98%; \ndisagreements were resolved \nby a third investigator. \nTwo independent and blinded \nreviewers evaluated risk for \nbias according to the PRIS-\nMA.  \nCochran Q test to evaluate \nheterogeneity and I2 testing \nwas used \nrandom-effects model was \nused because of heterogenei-\nty \nThey assessed the possibility \nof publication bias by using a \nfunnel plot \nNo role of funding source \nrisk of bias except for blinding \nand randomization not des-\ncribed \nno clinical endpoints like \nmortaliity or morbidity except \nhypoglycemia Metab. 2007;  \n25. Nauck MA et al. \nDiabetologia. 2007;  \n26. Reynolds LR, King-\nsley FJ, Karounos DG, \nTannock LR. Diabetes \nRes Clin Pract. 2007; \n27. Dorkhan M, Frid A, \nGroop L. Diabetes Res \nClin Pract. 2008; \n28. Kadoglou NP, Iliadis \nF, Angelopoulou N, \nPerrea D, Liapis CD, \nAlevizos M. Diabet Med. \n2008; \n29. Bergenstal R, Lewin \nA, Bailey T, Chang D, \nGylvin T, Roberts V; \nCurr Med Res Opin. \n2009;  \n30. Blickle\u00b4 JF et al. \nDiabetes Obes Metab. \n2009;  \n31. Hartemann-Heurtier \nA et al.. Diabetes Res \nClin Pract. 2009; \n32. Russell-Jones D et \nal; Diabetologia. 2009 G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4           5  \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \ntype 2 diabetes, \nnoninsulin antihy-\nperglycemic \nagents and insu-\nlins, \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nGross JL et al. (2011) [1] \nNetwork \nMeta-\nAnalysis, \nSystema-\ntischer \nReview McIntosh B \net al. \n(2011) \n[2]  Databases, type \nof study, search \nperiod:  \nMEDLINE, EM-\nBASE, BIOSIS \nPreviews, Pub-\nMed and the \nCochrane Central \nRegister of Con-\ntrolled Trials were One or more relevant \ndrugs either (1) added \nto metformin because of \ninadequate glycemic \ncontrol with metformin \nalone or (2) replacing \nmetformin because of \nintolerance. Outcomes:  \nHbA1c, hypoglycemia, body weight, \nquality of life, long-term complications of \ndiabetes, severe adverse events (drug \nrelated or otherwise) and mortality. \n #All classes of second-line agents added \nto metformin significantly reduced HbA1c \nrelative to metformin alone \n# there were no statistically significant methodological weaknesses \nand strenght: \n- Study selection, data ex-\ntraction and quality as-\nsessment were conducted \nindependently by 2 revie-\nwers. Risk of bias was as-\nsessed using the SIGN-50 \ninstrument. \n-  Bayesian mixed-treatment 27. Bosi E, Camisasca \nRP, Collober C, Ro-\nchotte E, Garber AJ. \nDiabetes Care 2007; \n28. Brazg R, Xu L, Dalla \nMan C, Cobelli C, Tho-\nmas K, Stein PP. \nDiabetes Obes Metab \n2007; \n30. Charbonnel B, 1(+) \nG\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4           6  \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nsearched for \nrandomized \ncontrolled trials \npublished in \nEnglish from 1980 \nto October 2009. \nAdditional cita-\ntions were obtai-\nned from grey \nliterature and \nconference \nproceedings \ninclusion and \nexclusion criteria: \nThe population of \ninterest consisted \nof adults and \nchildren with \nT2DM requiring a \nsecond-line \nantihyperglycemic \nagent because of \ninadequate con-\ntrol (hemoglobin \nA1c (HbA1c) > \n6.5%, fasting \nplasma glucose \n(FPG) > 7 mmol/L \non metformin \nmonotherapy or \nbecause of intole-\nrance to this \ntherapy. \nAgents from the differences between drug classes \n#Hypoglycemia: Thirty-four RCTs (n = 16 \n704). Relative to metformin monotherapy, \nrisk was significantly elevated with insu-\nlins, sulfonylureas and meglitinides (odds \nratios [ORs] were 5.2\u201311.0 for insulins \nand 8.2 for sulfonylureas). There were no \nsignificant differences between these \nclasses. \n#Body weight: Treatment with sulfonylu-\nreas, meglitinides, TZDs and biphasic \ninsulin resulted in significantly greater \nincreases in body weight than metformin \nmonotherapy (range 1.8\u20133.0 kg), with no \nsignificant differences between these \nclasses. \n# Long-term complications and severe \nadverse events: There were insufficient \ndata available for diabetes complications, \nmortality or quality of life. \nMost RCTs included in this review were of \ninadequate size or duration to detect \ndifferences in the occurrence of long-term \ncomplications of diabetes. On the basis of \ndata available, no significant differences \nbetween treatments were found \nDetails see below \n- Forty RCTs (n = 17 795)  \n- Most trials were 6\u201312 months long, \nalthough 1 study was over 5 years in \nduration.  Mean baseline HbA1c \nranged from 6.6% to 10% (weighted \nmean \u00b1 standard deviation [SD] 8.0% comparison (MTC) meta-\nanalysis was conducted \nbecause of necessitating \nindirect comparisons (Win-\nBUGS used) \n- system. literature search + \n- heterogeneity analysis +: \nAll analyses conducted as \nrandom effects models; I2  \nor other statist. values are \nnot shown (not in appendix \n6 either) \n- COI + \n- Flowchart + \n-  Sensitivity analysis+ \n- Publication bias was not \nassessed because of a li-\nmited number of studies for \neach pairwise comparison. \n-  A majority of the RCTs in \nthe analysis, including the \nlargest trials, received a \npoor rating upon as-\nsessment for risk of bias.  Karasik A, Liu J, Wu M, \nMeininger G.. Diabetes \nCare 2006; \n32. Charpentier G, \nFleury F, Kabir M, Vaur \nL, Halimi S. Diabet Med \n2001 \n33. DeFronzo RA, \nRatner RE, Han J, Kim \nDD, Fineman MS, Baron \nAD. Diabetes Care \n2005; \n35. Einhorn D, Rendell \nM, Rosenzweig J, Egan \nJW, Mathisen AL, \nSchneider RL. Clin Ther \n2000 \n38. Fonseca V, Ro-\nsenstock J, Patwardhan \nR, Salzman A. JAMA \n2000 \n41. G\u00f3mez-Perez FJ et \nal. Diabetes Metab Res \nRev 2002 \n42. Goodman M, Thurs-\nton H, Penman J. Horm \nMetab Res 2009 \n43. Halimi S, Le Berre \nMA, Grang\u00e9 V. Diabetes \nRes Clin Pract 2000 \n47. Kaku K. Curr Med \nRes Opin 2009; \n51. Leiter LA, Harris SB, G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4           7  \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nfollowing drug \nclasses were \nassessed: \nsulfonylureas, \nmeglitinides, \nthiazolidine-\ndiones, DPP-4 \ninhibitors, GLP-1 \nanalogues, insu-\nlins and insulin \nanalogues, alpha-\nglucosidase \ninhibitors and \nweight-loss \nagents (orlistat \nand sibutramine).  \u00b1 0.9%).  The baseline duration of \ndiabetes ranged from 1.8 to 10.3 years \n(weighted mean \u00b1 SD 6.1 \u00b1 5.1 years). \nMost studies (89%) were industry fun-\nded. About two-thirds of the studies \nidentified were of poor methodological \nquality; inadequate allocation conceal-\nment, failure to use an intention-to-treat \nanalysis and lack of blinding were \ncommon limitations.  Chiasson JL, Edwards \nL, O\u2019Neill MC, Van DM. \nCan J Diabetes 2005;. \n52. Marre M, Howlett H, \nLehert P, Allavoine T. \nDiabet Med 2002;. \n53. Marre M et al. \nDiabetes Obes Metab \n2002; \n56. Moses R et al. \nDiabetes Care \n1999;2007;9(2):194\u2013\n205. \n58. Nauck MA, \nHompesch M, Filipczak \nR, Le TDT, Zdravkovic \nM, Gumprecht J. Exp \nClin Endocrinol Diabetes \n2006; \n59. Nauck M et al. \nDiabetes Care 2009; \n61. Phillips P, Karrasch \nJ, Scott R, Wilson D, \nMoses R. Diabetes Care \n2003; \n62. Poon T et al. \nDiabetes Technol Ther \n2005; \n64. Raz I et al.Curr Med \nRes Opin 2008; \n67. Rodger NW et al. \nClin Invest Med 1995; \n68. Rosenstock J et al. G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4           8  \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nDiabetes Care 1998;  \n70. Scott R, Loeys T, \nDavies MJ, Engel SS; \nSitagliptin Study 801 \nGroup. Diabetes Obes \nMetab 2008; \n72. Van Gaal L, Maislos \nM, Schernthaner G, \nRybka J, Segal P.  \nDiabetes Obes Metab \n2001; \n77. DeFronzo RA et al. . \nDiabetes Care 2009; G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4           9  \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \n McIntosh B et al. (2011) [2]  \nG\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 10 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nMeta-\nAnalysis \nvon 5 \nKohor-\ntenstu-\ndien, kein \nSystema-\ntischer \nReview Carnethon \nMR et al. \n(2012) \n[3]  \n Pooled analysis of \nfive longitudinal \ncohort studies: \nAtherosclerosis \nRisk in Communi-\nties Study, 1990\u2013\n2006; Cardiovas-\ncular Health \nStudy, 1992\u2013\n2008; Coronary \nArtery Risk Deve-\nlopment in Young \nAdults, 1987\u2013\n2011; Fra-\nmingham \nOffspring  Study, \n1979\u20132007; Multi- \nEthnic Study of \nAtherosclerosis, \n2002\u20132011. \nParticipants \ncontributed \n27,125 person-\nyears of follow-up. \nNo systematic \nsearch of data-\nbases. Comparison between \nnormal weight and \noverweight/obese parti-\ncipants who had inci-\ndent diabetes Main Outcome Measures - Total, cardio-\nvascular, and non-cardiovascular mortali-\nty: \nparticipants with normal weight diabetes \nexperienced a significantly elevated total \nmortality  (hazard ratio [HR]=2.08, 95% \nCI: 1.52, 2.85) and non-cardiovascular \nmortality  (HR=2.32, 95% CI: 1.55, 3.48). \nAlthough the hazard for cardiovascular \nmortality  was elevated, the association \nwas not statistically significant (HR=1.52, \n95% CI: 0.89, 2.58). \nSetting - 2,625 participants with incident \ndiabetes. - cohort-specific analyses to \ngenerate effect estimates \nthat were pooled together \nusing fixed and random ef-\nfects meta-analysis. Be-\ncause effect estimates \nwere relatively homoge-\nnous across cohorts, there \nwere no differences bet-\nween fixed and random ef-\nfects and so they presented \nfixed effects \n- adjustment for waist cir-\ncumference, total choleste-\nrol, high density lipoprotein \ncholesterol, systolic blood \npressure and smoking sta-\ntus were done \n- COI not reported \n- Comorb. or comed. not \nreported \n- No systematic search of \ndatabases \n- unclear, whether research \nquestion a priori defined 9. Friedman GD et al. \nJournal of Clinical Epi-\ndemiology. 1988;  \n10. Fried LP et al. Ann \nEpidemiol. 1991;  \n11. ARIC Investigators. \nAmerican Journal of \nEpidemiology. 1989;  \n12. Bild DE et al.. Am J \nEpidemiol. 2002;  \n13. Feinleib M, Kannel \nWB, Garrison RJ, \nMcNamara PM, Castelli \nWP. Prev Med. 1975;  1-  \n(kein sys-\ntem. Re-\nview) \nSystema-\ntischer \nReview \n/Meta-\nAnalysis \n Lerch C, \nRichter B \n(2010) \n[4] RCT  \n- Suchzeitraum: \nwurde nicht \nangegeben \n- Datenbanken: \nGrundlage war Kombinationstherapie \nInsulin plus OAD versus \nInsulinmonotherapie \nKombinationspartner \nMetformin \nInsulin vs. Insulin plus - Studienanzahl: 22  zu 25 Vergleichen,  \n- Meta-Analysen wurden immer dann \ndurchgef\u00fchrt, wenn die Angaben f\u00fcr die  \nentsprechenden Endpunkte in den \njeweiligen Studien daf\u00fcr ausreichend \nwaren. \n-Endpunkte: HbA1c und K\u00f6rpergewicht, Methodische \nSchw\u00e4chen/Limitationen:  \n- Keine 2 reviewer \n- Keine Ausschlusskriterien \nangegeben \n- H\u00e4ufig keine KI angege-2. oudswaard AN, \nCochrane Database \nSyst Rev 2004; \n3. van Avendonk et al, \nDiabetes Obes Metab \n2009;  1- G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 11 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nsystematischer \nReview der \nCochrane Col-\nlaboration (2) \nund eine wei-\ntere Litera-\ntur\u00fcbersicht zur \nInsulintherapie \ndes Typ 2 \nDiabetes melli-\ntus (3). Eine \neigene syste-\nmatische Lite-\nraturrecherche \nin MEDLINE \nerfolgte zus\u00e4t-\nzlich.  \n- Ein- & Aus-\nschlusskrite-\nrien: \nEingeschlos-\nsen wurden \nrandomisierte \nklinische Stu-\ndien bei Pa-\ntienten mit \nDiabetes melli-\ntus Typ 2, die \nzuvor noch \nnicht dauerhaft \nmit Insulin be-\nhandelt \nwurden. Die \nStudien \nmussten \u00fcber Sulfonylharnstoff \nKombinationspartner \nMetformin und Sulfonyl-\nharnstoff \nKombinationspartner \nAcarbose \nKombinationspartner \nMetformin und Rosigli-\ntazon \nKombinationspartner \nMetformin und Repagli-\nnid  \nKombinationspartner \nPioglitazon schwere Hypoglyk\u00e4mien (keine patien-\ntenrelevanten Endpunkte wie Mortalit\u00e4t \nund Morbidit\u00e4t) \nSignifikante Ergebnisse: \n- Kombinationspartner Metformin:  \n- Vier Studien mit insgesamt 466 \nPatienten und einer Dauer zwi-\nschen 16 und 52 Wochen unter-\nsuchten die Hinzunahme von ver-\nschiedenen Insulintherapieformen \nzu Metformin (8-11). \n- In der Meta-Analyse: um 0,4 % \n(95 %- Konfidenzintervall [95 %-\nKI] von 0,02 bis 0,7) bessere \nHbA1c-Senkung unter der Kombi-\nnationstherapie von Insulin und \nMetformin gegen\u00fcber der alleini-\ngen Insulingabe. \n- Schwere Hypoglyk\u00e4mie: 10 Epi-\nsoden in der Insulin-Metformin-\nGruppe  gegen\u00fcber 1 Episode in \nder Insulinmonotherapiegruppe \n(relatives Risiko 9,5 mit 95 %-KI \n1,2 bis 72) (10). \n- Kombinationspartner Acarbose : \n- Hier wurde nur eine Studie von 20 \nWochen Dauer identifiziert (25). \n163 Patienten (mittleres Alter 62 \nJahre, 51 % Frauen, BMI 30 \nmg/m2, Diabetesdauer 7 Jahre, \nHbA1c 8,5 %). \n- Es zeigte sich ein um 0,5 % (95 \n%-KI 0,1 bis 0,9) bessere HbA1c-\nAbsenkung unter der Kombinati-ben,  \n- Suche nur in Medline \n- Kein Funnelplot f\u00fcr Erken-\nnen von Publikationsbias, \nkein Forrestplot bei Meta-\nAnalyse \n- Kein Test auf Heterogenit\u00e4t \n- Keine Qualit\u00e4tsbewertung \noder -beschreibung der \nber\u00fccksichtigten Studien \nbeschrieben, keine \ndiesbzgl. Ausschlusskrite-\nrien beschrieben \n- Keine Angabe des Such-\nzeitraums f\u00fcr Literaturre-\ncherche  \n- Viele gro\u00dfe RCT nicht \nenthalten, unklar, ob nicht \ngefunden (z. B. wegen \nkurzem Suchzeitraum oder \nausgeschlossen) \n- Kein Flowchart  \n 8. Yki-J\u00e4rvinen H et al,  \nAnn Intern Med 1999;  \n9. Civera M et al, Diab \nRes Clin Pract 2008;  \n10. Douek IF et \nal.,Diabet Med 2005 \n11. Kvapil M et al, \nDiabetes Obes Metab \n2006;  \n25. Schnell O et al, \nDiabetes Obes Metab \n2007;  \n26. Home PD et al,  \nDiabetic Med 2007;  \n27. Raz I et al, Clin Ther \n2005;  \n28. Fonseca VA et al, J \nDiabet Complications \n2006;  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 12 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \neinen Zeitraum \nvon mehr als \ndrei Monaten \ndurchgef\u00fchrt \nworden sein. \n onsgabe von Mischinsulin und \nAcarbose. Die Insulinmonothera-\npie ging mit einer mittleren Ge-\nwichtszunahme von 10 kg einher, \nw\u00e4hrend das K\u00f6rpergewicht unter \nKombinationstherapie praktisch \nunver\u00e4ndert war. \n- Kombinationspartner Metformin und \nRosiglitazon: (26) \n- Die kombinierte Therapie f\u00fchrte zu \neiner um 0,7 (95 %-KI 0,5 bis 0,7) \n% gr\u00f6\u00dferen HbA1c-Absenkung. \nSchwere Hypoglyk\u00e4mien traten \nnicht auf.  Verglichen zur Kombi-\nnationstherapie-Gruppe lag die \nGewichtszunahme in der Insulin-\nmonotherapiegruppe um 1,1 kg \n(95 %-KI 0,2 bis 2,1) h\u00f6her. \n- Kombinationspartner Pioglitazon : \n- In einer Studie war die mittlere \nHbA1c-Absenkung unter kombi-\nnierter Insulin-Pioglitazon-\nTherapie um 0,6 % (95 %-KI 0,2 \nbis 1) ausgepr\u00e4gter (27), auch in \nder zweiten Studie zeigte sich ein \nVorteil der Kombinationstherapie \n(28). \nSystema-\ntischer \nReview Bennett \nWL et al. \n(2011) \n[5] \nund  \nBennett \nWL et al. Suchzeitraum:  \nfrom inception \nthrough April \n2010 (December \n2010 for longterm \noutcomes) \nQuellen: Interventionen \nhead-to-head monothe-\nrapy or combination \ntherapy comparison of \noral diabetes medica-\ntion: Included Studies: 140 RCT, 26 observa-\ntional studies  \n1. Longterm Outcomes \nIncluded Studies: 66, 45 since 2007, the \nnew studies were generally of short dura-\ntion (less than 1 year) and had few long-\nterm events (such as deaths and cardio-Qualit\u00e4ts-bewertung mit dem \nGRADE System (alle vorhan-\ndenen Studien zu einem \nEndpunkt werden bewertet) \nSichere Aussagen sind nur \nbei \u00ab Strength of Evidence = \nHigh \u00bb m\u00f6glich !!   1++ \n(Qualit\u00e4t des \nReviews, \nnicht der \nStudien) G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 13 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \n(2011) \n[6] MEDLINE, Em-\nbase, and Co-\nchrane Central \nRegister of Con-\ntrolled Trials \ndatabases for \noriginal English-\nlanguage Articles, \nunpublished data \nfrom the Food \nand Drug Admi-\nnistration and \nothers \nTwo reviewers: \ntitle screening, \nquality as-\nsessment \n \n metformin, \nsecond-generation \nsulfonylureas, \nthiazolidinediones,  \nmeglitinides, \ndipeptidyl peptidase-4 \n(DPP-4) inhibitors, and  \nglucagon-like peptide-1 \nreceptor agonists \nComparisons  - Mono-\ntherapy as main inter-\nvention \n1. Metformin  versus : \nThiazolidinedione, \nSulfonylurea, DPP-4 \ninhibitor, Meglitinides, \nGLP-1 agonist, Combi-\nnation of metformin plus \nthiazolidinedione, Com-\nbination of metformin \nplus sulfonylurea,  \nCombination of metfor-\nmin plus DPP-4 inhibi-\ntor, Combination of \nmetformin plus megliti-\nnides, Combination of \nmetformin plus GLP-1 \nagonist \n2. Thiazolidinedione \nversus different thiazoli-\ndinedione, \u2022 Sulfonylu-\nrea, DPP-4 inhibitor, \nMeglitinides, GLP-1 vascular disease), making any estimates \nof risk difference very imprecise \n1a. All cause mortality \nStrength of the evidence low, Evidence \ninsufficient : \nLow All-cause mortality was slightly lower \nwith metformin than with a sulfonylurea in \nobservational studies, but results differed \nbetween trials and observational studies. \nRisk for bias in the studies was moderate. \nMany RCTs were short (1 y) and few \ndeaths occurred, limiting precision. \nSeveral comparisons did not address all-\ncause mortality; these included most \nDPP-4 inhibitor and GLP-1 agonist com-\nparisons, pioglitazone vs. rosiglitazone, \ncomparisons with an insulin preparation, \nand most combination therapy compari-\nsons. \n1b. Cardiovascular disease mortality \nStrength of evidence low, Evidence insuf-\nficient: \nCardiovascular mortality was slightly \nlower with metformin than with a sul-\nfonylurea, but results were imprecise and \nhad moderate risk for bias. \nRisk for cardiovascular mortality was \nsimilar between metformin and the thiazo-\nlidinediones as monotherapy, with high \nimprecision of results, inconsistencies, \nand moderate risk for bias. \nSeveral comparisons, including most \nDPP-4 inhibitor and GLP-1 agonist com-G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 14 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nagonist \n3. Sulfonylurea \nVersus DPP-4 inhibitor, \nMeglitinides, GLP-1 \nagonist \n4. DPP-4 inhibitor \nversus Meglitinides, \nGLP-1 agonist \nCombination therapy \nas main Intervention \n1.Combination of \nmetformin plus (a thia-\nzolidinedione or a sul-\nfonylurea or one of the \nmeglitinides or a DPP-4 \ninhibitor or a GLP-1 \nagonist or a basal \ninsulin or a premixed \ninsulin) versus \nCombination of metfor-\nmin plus (a thiazolidine-\ndione or a sulfonylurea \nor a meglitinides or \nDPP-4 inhibitor or GLP-\n1 agonist or a basal \ninsulin or a premixed \ninsulin) \n2. Combination of \nmetformin plus (a thia-\nzolidinedione or a sul-\nfonylurea or a megliti-\nnides or DPP-4 inhibitor \nor GLP-1 agonist or a parisons, pioglitazone vs. \nrosiglitazone, and most combination \ntherapy comparisons, did not address this \noutcome \n1c. Cardiovascular and cerebrovascu-\nlar disease morbidity \nStrength of Evidence low, Evidence \ninsufficient \n- Results were inconclusive for compari-\nson of metformin with a thiazolidine-\ndione, with high imprecision and incon-\nsistency of direction of findings. \n- Metformin decreased risk for fatal and \nnonfatal ischemic heart disease events \n(odds ratio, 0.43 [95% CI, 0.17 to 1.10]) \ncompared with the combination of \nmetformin and rosiglitazone, with a \nconsistent direction of results but high \nimprecision and lack of statistical signi-\nficance. \n- Several comparisons, including most \nDPP-4 inhibitor and GLP-1 agonist \ncomparisons, pioglitazone vs. rosiglita-\nzone, and most combination therapy \ncomparisons, did not address this out-\ncome. \n1d. Retinopathy, Neuropathy, \nNephropathy \nEvidence insufficient: \nNo studies addressed the outcome of \nretinopathy. \nStrengh of Evidence: low \nThree comparisons were included for the G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 15 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nbasal insulin or a pre-\nmixed insulin) versus \nCombination of a thiazo-\nlidinedione plus (a \nsulfonylurea or a megli-\ntinides or DPP-4 inhibi-\ntor or GLP-1 agonist) \nEndpunkte \nIntermediate out-\ncomes :  \nHbA1c \nWeight  \nLow Densiity Lipopro-\nteines \nHigh Density Lipopro-\nteins \nTriglyceride \nLong-term clinical \noutcomes \nAll cause mortality \nCardioascular mortality \nCardiovascular and \ncerebrovascular disease \nmorbidity \nRetinopathy \nNeuropathy \nNephropathy \nHarms \nHypoglycemia \nLiver Injury \nCongestive Heart Fai-outcome of neuropathy; studies had high \nrisk for bias, small sample sizes, and \npoorly defined outcomes. \nStrenght of evidence: moderate \nPioglitazone reduced the urinary albumin\u2013\ncreatinine ratio in 2 trials (by 15% and \n19%) over metformin, suggesting less \nnephropathy. \n2. Intermediate Outcomes \nIntermediate clinical outcomes were the \nmost frequently evaluated outcomes. We \nidentified 121 relevant articles with data \nfrom RCTs that addressed either HbA1c, \nbody weight, or lipids. \n2a. HbA1c-Wert \nStrengh of Evidence: High  \nMetformin and second-generation \nsulfonylureas showed similar changes in \nHbA1c, with a pooled between-group \ndifference of 0.07% (95% CI -0.12% to \n0.26%) for studies lasting longer than 3 \nmonths but usually less than 1 year in \nduration. \nStrength of Evidence: High  \nCombination therapies  were better than \nmonotherapy regimens at reducing \nHbA1c, with an absolute difference of \nabout 1%. In comparisons of metformin \nversus metformin plus thiazolidinediones, \nand metformin versus metformin plus \nsulfonylureas, the combination therapy \nwas favored for HbA1c reduction. \nStrengh of Evidence: Moderate  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 16 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nlure \nLactic Acidosis \nCancer \nSevere Allergic Reac-\ntion \nHip an Non-Hip Frac-\ntures \nAcute Pancreatitis \nCholecystitis \nMacular Edema \nGastrointestinal Effects \n When compared with DPP-4 inhibitors, \nmetformin had a greater reduction in \nHbA1c, with a pooled between-group \ndifference of -0.4% (95% CI -0.5% to -\n0.2%). \nStrength of Evidence; Moderate  \nComparisons of metformin versus thiazo-\nlidinediones, thiazolidinediones versus \nsulfonylureas, sulfonylureas versus repa-\nglinide, and pioglitazone versus rosiglita-\nzone showed similar reductions in HbA1c, \nwith an absolute reduction in HbA1c of \naround 1% as compared with baseline \nvalues, with trials lasting 1 year or less. \nStrength of Evidence:; Moderate  \nMetformin plus DPP-4 inhibitor was fa-\nvored over metformin alone for HbA1c \nreduction. \nStrength of Evidence: Moderate \nThe combination of metformin plus thiazo-\nlidinedione had a similar efficacy in redu-\ncing HbA1c as the combination of \nmetformin plus sulfonylurea. \nStrength of Evidence: Low  \nThe combination of pioglitazone plus \nsulfonylurea was minimally favored over \nmetformin plus pioglitazone, by an abso-\nlute difference of 0.03%. \nStrength of Evidence: Low  \nThe combination of metformin plus a \npremixed insulin analogue was minimally \nfavored over metformin plus a basal \ninsulin, by an absolute difference of G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 17 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \n0.30% to 0,43%. \n2b. Body Weight \nStrength of Evidence High  \nMetformin maintained or decreased \nweight to a greater extent than did thiazo-\nlidinediones (pooled between-group \ndifference of -2.6 kg, 95% CI -4.1 kg to -\n1.2 kg), the combination of metformin plus \na thiazolidinedione (pooled between-\ngroup difference of -2.2 kg, 95% CI -2.6 \nkg to -1.9 kg), or the combination of \nmetformin plus a sulfonylurea (pooled \nbetween-group difference of -2.3 kg, 95% \nCI -3.3 kg to -1.2 kg). Thiazolidinediones \nalone or in combination were associated \nwith weight gain. \nStrength of Evidence High  \nMetformin maintained or decreased \nweight to a greater extent than did sul-\nfonylureas, with a pooled between-group \ndifference of -2.7 kg (95% CI -3.5 kg to -\n1.9 kg).  \nStrength of Evidence High  \nSulfonylureas and the meglitinides had \nsimilar effects on body weight.  \nStrength of Evidence Moderate  \nGLP-1 agonists decreased weight to a \ngreater extent than did sulfonylureas \n(pooled between-group difference of -2.5 \nkg, 95% CI -3.8 kg to -1.1 kg). \nStrength of Evidence Moderate  \nMetformin plus sulfonylurea had a more G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 18 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nfavorable effect on weight than did either \nthe combinations of a thiazolidinedione \nplus sulfonylurea (pooled between-group \ndifference of -3.2 kg, 95% CI -5.2 kg to -\n1.1 kg) or metformin plus a thiazolidine-\ndione (pooled between-group difference \nof -0.9 kg, 95% CI -1.3 kg to -0.4 kg). \nStrength of Evidence Moderate  \nMetformin decreased weight to a greater \nextent than did DPP-4 inhibitors (pooled \nbetween-group difference of -1.4 kg, 95% \nCI -1.8 kg to -1.0 kg). \nStrength of Evidence Moderate  \nMetformin had no significantly different \neffect on weight than did the combination \nof metformin plus DPP-4 inhibitors (poo-\nled between-group difference of -0.2 kg, \n95% CI -0.7 kg to 0.2 kg). \nStrength of Evidence Low  \nMetformin plus GLP-1 agonists decreased \nweight to a greater extent than did several \ncombination therapies (metformin plus \nsulfonylurea, metformin plus thiazolidine-\ndione, metformin plus basal insulin, or \nmetformin plus DPP-4 inhibitor). \nStrength of Evidence Low  \nMetformin plus DPP-4 inhibitors decrea-\nsed weight to a greater extent than did \ntwo standard combinations, metformin \nplus thiazolidinedione or metformin plus \nsulfonylurea. \n2c. LDL Cholesterol G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 19 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nStrength of Evidence: High  \nMetformin decreased LDL to a greater \nextent than did sulfonylureas, which \ngenerally had little effect on LDL, with a \npooled between-group difference of -10.1 \nmg/dL (95% CI -13.3 mg/dL to -7.0 \nmg/dL). \nStrength of Evidence: High  \nThe combination of metformin and rosigli-\ntazone decreased LDL to a lesser extent \nthan did metformin monotherapy (pooled \nbetween-group difference of 14.5 mg/dL, \n95% CI 13.3 mg/dL to 15.7 mg/dL), \nStrength of Evidence Moderate  \nMetformin decreased LDL cholesterol to a \ngreater extent than did pioglitazone, \nwhich increased LDL cholesterol, with a \npooled betweengroup difference in LDL of \n-14.2 mg/dL (95% CI -15.3 mg/dL to -13.1 \nmg/dL). \nStrength of Evidence Moderate  \nMetformin decreased LDL cholesterol to a \ngreater extent than did rosiglitazone, with \na pooled between-group difference in LDL \nof -12.8 mg/dL (95% CI -24.0 mg/dL to -\n1.6 mg/dL). \nStrength of Evidence Moderate  \nMetformin decreased LDL to a greater \nextent than did DPP-4 inhibitors,with a \npooled between-group difference of -5.9 \nmg/dL (95% CI -9.7 mg/dL to -2.0 mg/dL). \nStrength of Evidence Moderate  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 20 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nThe combination of metformin and rosigli-\ntazone decreased LDL to a lesser extent \nthan did a combination of metformin and a \nsecondgeneration sulfonylurea, with a \npooled between-group difference in LDL \nof 13.5 mg/dL (95% CI 9.1 mg/dL to 17.9 \nmg/dL). \n2d HDL cholesterol \nStrength of Evidence High  \nMetformin increased HDL to a lesser \nextent than did pioglitazone, with a pooled \nbetween group difference of -3.2 mg/dL \n(95% CI -4.3 mg/dL to -2.1 mg/dL). \nStrength of Evidence High  \nSulfonylureas were similar to metformin in \nterms of changes in HDL. \nStrength of Evidence High  \nThe combination of metformin and rosigli-\ntazone increased HDL to a greater extent \nthan did metformin monotherapy (pooled \nbetween-group difference 2.8 mg/dL, 95% \nCI 2.2 mg/dL to 3.5 mg/dL). \nStrength of Evidence Moderate  \nRosiglitazone increased HDL to a lesser \nextent than did pioglitazone (pooled \nbetween-group difference of -2.3 mg/dL, \n95% CI -3.5 mg/dL to -1.2 mg/dL). Ro-\nsiglitazone alone was similar to metformin \nin terms of changes in HDL. Pioglitazone \nincreased HDL to a greater extent than \ndid sulfonylureas (pooled between-group \ndifference of 4.3 mg/dL, 95% CI 1.9 \nmg/dL to 6.6 mg/dL). The combination of G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 21 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nmetformin and pioglitazone increased \nHDL by about 5 mg/dL relative to the \ncombination of metformin and a sulfonylu-\nrea.  The combination of metformin and \nrosiglitazone increased HDL to a greater \nextent than did the combination of \nmetformin and a sulfonylurea (pooled \nbetween-group difference 2.7 mg/dL, 95% \nCI 1.4 mg/dL to 4.1 mg/dL). \nStrength of Evidence Moderate \nThe combination of metformin and DPP-4 \ninhibitors had similar effect on HDL as did \nmetformin monotherapy (pooled between-\ngroup difference was 0.5 mg/dL, 95% CI -\n1.5 mg/dL to 2.5 mg/dL). \nStrength of Evidence Low \nThe combination of pioglitazone with \nanother medication was favored for the \nfollowing comparisons: pioglitazone plus \nmetformin versus metformin monothe-\nrapy, metformin plus pioglitazone versus \nmetformin plus sulfonylurea, and pioglita-\nzone plus sulfonylurea versus metformin \nplus sulfonylurea, with a range of bet-\nween-group differences from 3.1 mg/dL \nto10.5 mg/dL. \n2e. Triglycerides \nStrength of Evidence High \nPioglitazone decreased TG to a greater \nextent than did metformin (pooled bet-\nween-group difference -27.2 mg/dL, 95% \nCI -30.0 mg/dL to -24.4 mg/dL). \nStrength of Evidence  High  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 22 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nMetformin monotherapy decreased TG to \na greater extent than did the combination \nof metformin and rosiglitazone, with a \npooled between-group difference in TG of \n-14.5 mg/dL (95% CI -15.7 mg/dL to -13.3 \nmg/dL). \nStrength of Evidence Moderate  \nMetformin decreased TG to a greater \nextent than did rosiglitazone, which in-\ncreased TG, with a pooled between-group \ndifference of -26.9 mg/dL (95% CI -49.3 \nmg/dL to -4.5 mg/dL). Metformin decrea-\nsed TG to a greater extent than did sul-\nfonylureas (pooled between-group diffe-\nrence -8.6 mg/dL, 95% CI -15.6 mg/dL to \n-1.6 mg/dL). \nStrength of Evidence Moderate \nThe combination of metformin plus rosigli-\ntazone and the combination of metformin \nplus sulfonylurea had similar effects on \nTG. The combination of metformin and \npioglitazone decreased TG to a greater \nextent than did the combination of \nmetformin and a sulfonylurea, with bet-\nween-group differences ranging from -10 \nmg/dL (p = 0.30) to -24.9 mg/dL (p = \n0.045). \nStrength of Evidence Moderate  \nSulfonylureas and meglitinides had similar \neffects on TG (pooled between-group \ndifference 0.2 mg/dL, 95% CI -3.8 mg/dL \nto 4.2 mg/dL). \n3. Adverse outcomes G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 23 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \n3.1 Hypoglycemia \nStrength of Evidence High  \nThe risk of mild to moderate hypoglyce-\nmia with sulfonylureas exceeds the risk \nwith metformin, with a pooled OR of 4.6 \n(95% CI 3.2 to 6.5). The range of rates for \nmild to moderate hypoglycemia in the \nmetformin group was 0 to 17.7%, with a \nmedian rate of 0%. The risk of mild to \nmoderate hypoglycemia with sulfonylu-\nreas exceeds the risk with thiazolidine-\ndiones, with a pooled OR of 3.9 (95% CI \n3.0 to 4.9). The range of rates for mild to \nmoderate hypoglycemia in the thiazolidi-\nnedione group was 0 to 92.1%, with a \nmedian rate of 4.4%. The risk of hypogly-\ncemia with metformin plus sulfonylurea \nexceeds the risk of metformin plus thiazo-\nlidinediones, with a pooled OR of 5.8 \n(95% CI 4.3 to 7.7). The range of rates for \nmild to moderate hypoglycemia in the \nmetformin plus thiazolidinediones group \nranged from 0 to 9.3%, with a median rate \nof 1.3%. \nStrength of Evidence Moderate  \nThe risk of hypoglycemia with sulfonylu-\nrea exceeds the risk with DPP-4 inhibitors \n(20 events versus none in a single study).   \nThe risk of hypoglycemia was similar \nbetween metformin and thiazolidine-\ndiones. \nThe risk of hypoglycemia with metformin \nplus sulfonylurea exceeded the risk with \nmetformin alone, with an OR range of 0.6 G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 24 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nto 9.3. \nThe risk of hypoglycemia was modestly \nhigher for meglitinides than for metformin, \nwith an OR of 3.0 (95% CI 1.8 to 5.2). The \nrange of rates for mild to moderate hypo-\nglycemia in the metformin group ranged \nfrom 0 to 24%, with a median rate of \n3.7%. \nThe risk of hypoglycemia was higher for \nmetformin plus a thiazolidinedione than \nfor metformin alone, with an OR of 1.6 \n(95% CI 1.0 to 2.4). The range of rates for \nmild to moderate hypoglycemia in the \nmetformin group ranged from 0 to 9.1%, \nwith a median rate of 1.4%. \nThe combination of metformin and DPP-4 \ninhibitor had similar risk of hypoglycemia \nas that of metformin alone. \nThe combination of metformin with a \nsulfonylurea had a higher risk of hypogly-\ncemia than metformin with GLP-1 ago-\nnists \nMetformin combined with a basal insulin \nhad a modestly lower risk of hypoglyce-\nmia when compared to metformin combi-\nned with a premixed insulin, with the RR \nranging from 0.34 to 0.94 in 5 trials. \n3b. Gastrointestinal Side Effects \nStrength of Evidence High  \nMetformin was associated with twice as \nmany GI adverse events, most commonly \ndiarrhea, nausea, and vomiting, as were \nthiazolidinediones. The rates of GI ad-G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 25 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nverse effects were similar for thiazolidine-\ndiones and sulfonylureas. \nStrength of Evidence Moderate  \nMetformin was associated with more \nfrequent GI adverse events than were \nDPP-4 inhibitors. Metformin was asso-\nciated with twice as many GI adverse \nevent rates as were second-generation \nsulfonylureas.  Metformin monotherapy \nwas associated with more frequent GI \nadverse events than were either the \ncombination of metformin plus a sul-\nfonylurea or metformin plus a thiazolidi-\nnedione, if the metformin component was \nof a lower dose than in the metformin \nmonotherapy arm. \nStrength of Evidence Moderate \nThe combination of metformin and sul-\nfonylurea was associated with slightly \nmore frequent GI adverse events than \nwere seen with a combination of a thiazo-\nlidinedione and a sulfonylurea. \n3c. Congestive heart failure \nStrength of Evidence Moderate  \nThe risk of CHF was higher for thiazolidi-\nnediones than for sulfonylureas (OR 1.68, \n95% CI 0.99 to 2.85). \nEvidence insufficient \nNo long-term trials assessed the compa-\nrative effects of the DPP-4 inhibitors and \nGLP-1 agonists on the risk of heart failure \n3d. Cholecystitis and pancreatitis G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 26 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nStrength of Evidence Low \nTwo comparisons were included for the \noutcome of cholecystitis, and one compa-\nrison was included for the outcome of \npancreatitis, with unclear conclusions. \n3e. Lactate acidosis \nStrength of Evidence Moderate  \nThe risk of lactic acidosis was similar for \nmetformin and sulfonylurea alone and for \nthe two in combination. \n3f. Macula Edema \nEvidence insufficient \nOnly one trial reported on macular ede-\nma. The evidence was insufficient for all \ncomparisons. \n3g. Cancer \nEvidence insufficient \nFew studies addressed the outcome of \ncancer. \n3h Liver injury \nStrength of Evidence High  \nThe risk of liver injury was similar for \nthiazolidinediones and sulfonylureas. \nStrength of Evidence Moderate  \nThe rates of liver injury were similar \nbetween thiazolidinediones and metfor-\nmin. \n3i. Fractures \nStrength of Evidence High  \nThe risk of fracture was higher for thiazol-\nidinediones than for metformin. In one G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 27 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nlarge RCT the RR was 1.57 (95% CI 1.13 \nto 2.17) and women in the thiazolidinedi-\none arm had a higher fracture risk than \nmen. The fracture rate was 4.1% in the \nreference (metformin) arm. The risk of \nfracture was higher for combination ther-\napy with a thiazolidinedione than for \nmetformin plus sulfonylurea, with higher \nrisk in women than in men. In one large \nRCT, the RR was 1.57 (95% CI 1.26 to \n1.97) for the rosiglitazone combination \ntherapy arm, as compared to the combi-\nnation of metformin plus sulfonylurea \narms. The fracture rate in the reference \n(metformin + sulfonylurea) arm was 1.6%. \nSystema-\ntischer \nReview \n Esposito K \net al. \n(2012) \n[7] Suchzeitraum: \nBis 4/2011 \nQuellen: \nMedline, Embase, \nCochrane Central, \nCinahl, Websei-\nten, Referenzlis-\nten \nalle Sprachen \nExtraktion durch 2 \nPersonen \nStudien:  \nRCT \nErgebnisse nach \nmind. 12 Wo \nBehandlung  \nMind. 30 Stu-Zusatz von einem nicht-\nInsulin zur Behandlung \ndes Typ-2-DM, bzw. \nNeubeginn der Behand-\nlung: \n1. Metformin, \n2. Sufonylharnstoffe, \n3. alpha-Glucosidase-\nInhibitoren, \n4. Glinide, \n5. GLP-1-Analoga \n(Inkretinmimetika), \n6. Thiazolidinedion, \n7. di-Peptyl-Peptidase-\n4-Inhibitoren (DPP4-\nInhib.), \n8. Insulinanaloga \nEndpunkte:  Eingeschlossene Studien: \n218 RCT publ. 1994-2011 mit 78.945 \nPatienten f\u00fcr prim\u00e4ren Endpunkt \n82 RCT publ. ab 2007 \n1 Cross-over, sonst Parallel-Design \nmeist multinational und industrie-\ngesponsert \n122 mind. doppelt blind \nIn 83 RCT Pat. vorher ohne Medikation \nbzw. vorher Absetzen anderer Medikation \nStudiendauer:  \n12-134 Wochen, meist 24-26 Wochen \nEingeschl. Patienten: \nmittl. Alter 50,2-62,7J \nMittl. HbA1c-Wert 7,2-11,7% \nGepoolte Ergebnisse Alle Ergebnisse unterliegen \neiner Heterogenit\u00e4t I\u00b2 \u00fcber \n85%. \nDie Autoren sehen das nicht \nals Problem. \nEs ist unklar, welche Quali-\nt\u00e4tsbewertung die einzelnen \nStudien hatten. \nEs wird nur \u00fcber HbA1c-Wert \nals Endpunkt berichtet. \n \n Als e-Referenz Nr, 1-\n218 (siehe bei Literatur \nam Ende der Evidenz-\ntabellen) 1- G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 28 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \ndienteilnehmer in \njedem Arm \nMedikation in \n\u00fcblicher/ empfoh-\nlener Dosierung \nStudienbeurtei-\nlung mit Jadad-\nScore, 5-stufig \n<3 schlechte \nQualit\u00e4t \nPatienten: \nNur Typ-2-DM, \nmind. 18J, nicht \nschwanger,  \nOhne Medikation \noder mit beste-\nhender Medikati-\non \n Prim\u00e4rer Endpunkt: \nHbA1c-Wert < 7% \ngepoolt, gewichtet, + \nStandardabweichung \nvom Logarithmus \nWeiterer Endpunkt: \nMittl. \u00c4nderung des \nHbA1c-Werts \nHeterogenit\u00e4tsbeurtei-\nlung mit Q-Statistik und \nI\u00b2. \u2013 Falls Heterogenit\u00e4t: \nRandom Effects Modell, \nsonst Fixed Effects \nModell. 1.Metformin \n4.827 Pat., 21 Arme,  \nMittl HbA1c-Wert basal 8,55% (0,78) \nMittl. \u00c4nderung HbA1c-Wert : -1,21 (0,48) \nHbA1c-Wert<7% 42%[35,5-48,9], I\u00b2 94,2 \n2. Sulfonylharnstoffe \n5.895 Pat. , 24 Arme \nMittl HbA1c-Wert basal 7,91% (0,45) \nMittl. \u00c4nderung HbA1c-Wert : -0,77 (0,29) \nHbA1c-Wert<7% 48,2%43-53,5], I\u00b293,2 \n3. Alpha-Glucosidase-Inhibitoren \n1.120 Pat, 13 Arme, \nMittl. HbA1c-Wert basal 8,39% (0,57) \nMittl. \u00c4nderung HbA1c-Wert 0,72 (0,41) \nHbA1c-Wert<7% 25.9% [18,5-34,9], I\u00b2 \n89,4 \n4. Glinide \n1.050 Pat., 9 Arme, \nMittl. HbA1c-Wert basal 8,15% (0,38) \nMittl. \u00c4nderung HbA1c-Wert -0,64 (0,29) \nHbA1c-Wert<7% 39,1%[29,3-49,9], I\u00b2 \n90,4 \n5a. GLP-1-Analoga t\u00e4gl. \n5.783 Pat. , 33 Arme \nMittl HbA1c-Wert basal 8,38% (0,35) \nMittl. \u00c4nderung HbA1c-Wert -1,12 (0,23) \nHbA1c-Wert<7% 45,7%[42,2-49,2], I\u00b285,4 \n5b. GLP-1-Analoga LAR (w\u00f6chentl.) \n668 Pat. , 4 Arme \nMittl. HbA1c-Wert basal   8,41 (0,13) \nMittl. \u00c4nderung HbA1c-Wert -1,61 (0,16) G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 29 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nHbA1c-Wert<7% 63,2%[54,2-71,5], I\u00b281,7 \n6. Thiazolidinedion \n6.655 Pat. , 41 Arme \nMittl. HbA1c-Wert basal  8,62 (0,64) \nMittl. \u00c4nderung HbA1c-Wert -0,96 (0,32) \nHbA1c-Wert<7% 33,2%[28,5-38,2], I\u00b293,1 \n7. DPP4-Inhibitoren \n13.847 Pat. , 60 Arme \nMittl. HbA1c-Wert basal  8,11 (0,55) \nMittl. \u00c4nderung HbA1c-Wert -0,74 (0,30) \nHbA1c-Wert<7% 39%[35,7-42,3], I\u00b293,2 \n8. Insulinanaloga \n8a. Basale Gabe \n21.615 Pat.,57 Arme, \nMittl. HbA1c-Wert basal 8,79% (0,26) \nMittl. \u00c4nderung HbA1c-Wert -1,28 (0,36) \nHbA1c-Wert<7% 38,9%[35,7-42,2], I\u00b2 \n95,1 \n8b. Biphasische Gabe  \n11.921 Pat, 51 Arme \nMittl. HbA1c-Wert basal 9,30% (0,60) \nMittl. \u00c4nderung HbA1c-Wert -1,91 (0,64) \nHbA1c-Wert<7% 34,4%[31,1 37,9], I\u00b2 92,1 \n8c. Prandiale Gabe \n2.579 Pat., 13 Arme \nMittl. HbA1c-Wert basal 8,66% (0,54) \nMittl. \u00c4nderung HbA1c-Wert -1,08 (0,68) \nHbA1c-Wert<7% 36,34%[26,3-47,7], I\u00b2 \n96,1 \n8d. Basal-Bolus Gabe G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 30 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \n2.967 Pat., 16 Arme \nMittl. HbA1c-Wert basal 8,33% (0,52) \nMittl. \u00c4nderung HbA1c-Wert -1,22 (0,58) \nHbA1c-Wert<7% 50,2%[43,0-57, 4], I\u00b2 \n93,0 \nStratifizierte Ergebnisse \nWe divided all arms in 7 strata from  \nbaseline HbA1c.(from < 7,5 to > 10,0). \nThere was a progressive decrease of the \nproportion of patients at target for each \n0,5% increment of baseline HbA1c, rang-\ning from 57,8% of baseline </= 7 to 20,8% \nof baseline >/=10.(p for trend <0,0001). \nSimilarly, there was a progressive in-\ncrease in HbA1c reduction ranging from -\n0,53 to -2,17 (p<0,0001). \nWe further stratified all 342 arms in insulin \n(137arms, 39.100 Pat) and non-insulin \ndrugs (205, 39.845 Pat.). The relation for \nbaseline HbA1c reached a plateau for \nInsulin for basal HbA1C> 9% for insulin, \nwhile the same relation for non-insulin \ndrugs was continouos without  any evi-\ndence of plateau.  \nThe relation between baseline HbA1c and \nreduction in HbA1c was linear for insulin \nbut was no more evident at the highest \nbaseline values for non-insulin drugs \nSystema-\ntischer \nReview mit \nMeta-\nAnalyse Hemming-\nsen B. et \nal. (2012) \n[8]  Suchzeitraum: \nuntil March 2011. \nQuellen:  \nThe Cochrane Interventionen:  \nMetformin + insulin \nversus insulin alone \nEndpunkte: Included Studies:  \n30 publications describing 26 randomised \nclinical trials, randomly assigning 2.286 \npatients to metformin and insulin versus \nto insulin alone. Three trials could not Assessment of Risk of bias \nwith the Cochrane Instrument  \na random effects model and a \nfixed effect was used. In case \nof discrepancy between the  1+/- \n(- f\u00fcr long-\nterm out-\ncomes) G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 31 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \n Library, Medline, \nEmbase, Science \nCitation Index \nExpanded, Latin \nAmerican Carib-\nbean Health \nSciences Litera-\nture and Cumula-\ntive Index to \nNursing and Allied \nHealth Literature, \nAbstracts pre-\nsented at the \nAmerican Diabe-\ntes Association \nand European \nAssociation for \nthe Study of \nDiabetes, Con-\ngresses,  \nContact of rele-\nvant trial authors \nand pharmaceuti-\ncal companies, \nhand searched \nreference lists of \nincluded trials, \nand searched the \nUS Food and \nDrug Administra-\ntion website. \nStudien: \nRCT comparing \nmetformin and Primary outcomes:  \nAll Cause Mortality \nCardiovascular Mortaliy \nSecondary outcomes: \nmacrovascular and \nmicrovascular diseases \nassessed as composite \noutcomes and in sepa-\nrate (non-fatal myocar-\ndial infarction, non-fatal \nstroke, abdominal aorta \naneurism, amputation of \nlower extremity, cardial \nor peripheral revascular-\nisation, manifestation \nand progression of \nnephropathy, end stage \nrenal disease, manifes-\ntation and progression \nof retinopathy, or retinal \nphotocoagulation) \nadverse events, cancer, \nquality of life, costs of \nintervention, insulin \ndose, glycaemic control, \nweight, and blood pres-\nsure provide data for the meta-analysis be-\ncause they only described the total num-\nber of patients who underwent randomisa-\ntion.29 30 Accordingly, 23 trials (2117 \nparticipants) provided data for our anal-\nyses. \nStrength of the evidence \nAll trials had high risk of bias. Data were \nsparse for outcomes relevant to patients. \nAll Cause Mortality/Cardiovascular \nMortality \nMetformin and insulin versus insulin alone \ndid not significantly affect all cause mor-\ntality (relative risk 1.30, 95% confidence \ninterval 0.57 to 2.99,p=0,77  I \u00b2= 0) or \ncardiovascular mortality (1.70, 0.35 to \n8.30, p=0,52, I\u00b2=0). Trial sequential anal-\nyses showed that more trials were need-\ned before reliable conclusions could be \ndrawn regarding these outcomes. \nIntermediate outcomes \nIn a random effects model, metformin and \ninsulin resulted in reduced HbA1c, weight \ngain, and insulin dose, compared with \ninsulin alone; trial sequential analyses \nshowed sufficient evidence for a HbA1c \nreduction of 0.5%, lower weight gain of 1 \nkg, and lower insulin dose of 5 U/day. \nAdverse effects \nIn a fixed effect model, but not in a ran-\ndom effects model, severe hypoglycaemia \nwas significantly more frequent with \nmetformin and insulin than with insulin two models, both results were \nreported. \u00b4 \nExamination of heterogeneity \nwith the I2 statistic (I2 \u226550% \nindicated substantial hetero-\ngeneity). G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 32 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \ninsulin versus \ninsulin alone (with \nor without place-\nbo) and with an \nintervention \nperiod of at least \n12 weeks \nall languages  \nall outcomes \ninclusion irrespec-\ntive of publication \nstatus and out-\ncomes \nPatienten: \nPatients with type \n2 diabetes, older \nthan 18 years alone (2.83, 1.17 to 6.86) \nSystema-\ntischer \nReview mit \nMeta-\nAnalyse Karagian-\nnis T et al. \n(2012) \n[9] Suchzeitraum \n1980 to 2011 \nThe last search \nwas run on 15 \nMarch 2011. \nSearch of ab-\nstracts 2009/2010 \nQuellen: \nNo language \nrestriction \nMedline, Embase, \nthe Cochrane \nLibrary, confer-\nence proceed-\nings, trial regis-Interventionen: \nComparison of DPP-4 \nwith metformin as \nmonotherapy or with a \nsulfonylurea, pioglita-\nzone, a glucagon-like \npeptide-1 (GLP-1) \nagonist, or basal insulin \ncombined with metfor-\nmin \nEndpunkte: \nPrimary endpoint: \nchange of baseline \nHbA1c  Included studies \n27 reports (15 published primary studies, \neight published extensions, three un-\npublished extensions, and one confer-\nence abstract) with 7.136 patients ran-\ndomised to a DPP-4 inhibitor and 6745 \npatients randomised to another hypogly-\ncaemic drug were included in the system-\natic review and meta-analyses. 12 reports \ncompared a DPP-4 inhibitor with metfor-\nmin as monotherapy. A DPP-4 inhibitor \ncombined with metformin was compared \nwith metformin combined with a sulfonylu-\nrea, pioglitazone, and a GLP-1 agonist in \nnine, and three reports respectively. \nStudy  characteristics Bias Assessment mit \nCochrane Collaboration\u2019s risk \nof bias tool  1++ \n(Qualit\u00e4t des \nReviews, \nnicht der \nzugrundelie-\ngenden \nStudien) G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 33 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nters, and drug \nmanufacturers\u2019 \nwebsites. \nStudien: \nRandomised \ncontrolled trials \nthat compared a \nDPP-4 with met-\nformin as mono-\ntherapy or with a \nsulfonylurea, \npioglitazone, a \nglucagon-like \npeptide-1 (GLP-1) \nagonist, or basal \ninsulin combined \nwith metformin  \nPatienten: \nadults with type 2 \ndiabetes mellitus Almost all studies were multicentre and \nsponsored by pharmaceutical companies. \nAll studies were parallel and included an \nactive control group in a double blind \ndesign, except for the study by Pratley et \nal32 40 (open label design), the study by \nForst et al29 (in which patients were \nrandomised to receive double blind \nlinagliptin (1, 5, and 10 mg) or placebo or \nopen label glimepiride), and the study by \nHandayani et al42 (no blinding men-\ntioned). Nine reports (six primary studies \nand three extensions) were published in \n2010, while three (one primary study and \ntwo extensions) were published in 2011. \nof intervention was equal to or longer than \none year (52 weeks). The duration in 12 \nstudies (including their extension periods). \nThe primary end point in all studies was \nthe change in HbA1c from baseline. \nParticipants\u2019 baseline characteristics were \nequally balanced between the study arms \nin each study \nRisk of bias assessment  \nRandom sequence generation and alloca-\ntion concealment were described ade-\nquately in 16 and 10 of the 27 eligible \nreports, respectively. Overall risk of bias \nfor the primary outcome was low in \nthree, unclear in nine nd high in 14 \nreports (mainly because of inadequate \nhandling of outcome data (per protocol \nanalysis) or attrition bias resulting \nfrom high discontinuation rate) . We did \nnot assess risk of bias for the study of G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 34 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nHandayani et al because it was available \nonly as an abstract. There was no evi-\ndence of publication bias from the visual \ninterpretation of the funnel plot or Egger\u2019s \ntest (P=0.363) \n1. Intermediate outcomes \n1a. HbA1c/Glycemic control \nSeven trials (n=3237) comparing a DPP-4 \ninhibitor with metformin monotherapy and \n10 trials (n=8912) that compared DPP-4 \ninhibitors with other hypoglycaemic drugs \ncombined with metformin contributed to \nthis analysis. \nCompared with metformin monothera-\npy, DPP-4 inhibitors were associated with \na smaller decline in HbA1c (weighted \nmean difference 0.20, 95% confidence \ninterval 0.08 to 0.32, 95% prediction \ninterval \u22120.14 to 0.54; I2=60%) (fig 2\u21d3 ) \nand a lower chance of attainment of the \nHbA1c goal of less than 7% (risk ratio in \nfavour of metformin 1.18, 95% confidence \ninterval 1.07 to 1.29, I2=34%) (fig 3 \u21d3). \nExclusion of the reports at high risk of \nbias did not alter the effect estimate or \nheterogeneity \nAs a second line treatment,  DPP-4 \ninhibitors achieved a smaller decline in \nHbA1c than the other hypoglycaemic \ndrugs (overall weighted mean difference \n0.12, 0.04 to 0.2, 95% prediction interval \n\u22120.13 to 0.37; I2=70%). Exclusion of \nreports at high risk of bias did not alter the \neffect estimate or heterogeneity.  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 35 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nData analysis separately for each type \nof active comparator , DPP-4 inhibitors \nwere less effective than sulfonylureas in \nreducing HbA1c (weighted mean differ-\nence 0.07, 0.03 to 0.11, 95% prediction \ninterval 0.02 to 0.13; I2=0%) There was \nno significant difference, however, in the \nattainment of the HbA1c goal of less than \n7% (risk ratio in favour of sulfonylureas \n1.06, 0.98 to 1.14; I2=26%)). \nThere was no difference in the change \nin HbA1c achieved between DPP-4 \ninhibitors and pioglitazone  (weighted \nmean difference 0.09, \u22120.07 to 0.24, 95% \nprediction interval \u22121.4 to 1.57, I2=40%) . \nPioglitazone,  however, was associated \nwith a higher chance of reaching the goal \nof less than 7% (risk ratio in favour of \npioglitazone 1.33, 1.09 to 1.63, I2=0%) \nDPP-4 inhibitors were inferior to GLP-1 \nagonists  both in reducing HbA1c \n(weighted mean difference 0.49, 0.31 to \n0.67; I2=27%) and in achieving the gly-\ncaemic goal of less than 7% (risk ratio in \nfavour of GLP-1 agonists 1.33, 1.09 to \n1.63; I2=26%) \n1b. Body Weight \nTwelve trials (n=9156) contributed data in \nthe main analysis for the change in body \nweight.  \nAs monotherapy, DPP-4 inhibitors \nwere less effective in decreasing body \nweight than metformin  (weighted mean \ndifference 1.50, 0.90 to 2.11;I2-74%).  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 36 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nWhen added to metformin, DPP-4 \ninhibitors had a favourable weight profile \ncompared with sulfonylureas (\u22121.92, \n\u22122.34 to \u22121.49; I2=69%) or pioglitazone \n(\u22122.96, \u22124.13 to \u22121.78; I2=79%) but not \ncompared with GLP-1 agonists (1.56, \n0.94 to 2.18; I2=0%). \n2. Longterm outcomes \n2.1 All Cause Mortality \nInformation on mortality ... was available \nin almost all  trials. None of the trials, \nhowever, was designed to analyse this  \noutcome. All cause mortality did not differ \nbetween DPP-4 inhibitors and any of the \ncomparator.There were 23 deaths in \npatients receiving a DPP-4 inhibitor \n(n=6.789) and 28 deaths in patients \nreceiving an active comparator (n=6.505).  \n3. Adverse events \nInformation on serious adverse events \navailable in almost all  trials. None of the \ntrials, however, was designed to ana-lyse \nthis  outcome Incidence of any serious \nadverse event was lower with DPP-4 \ninhibitors than with pioglitazone (risk ratio \n0.47, 0.27 to 0.82; I2=0%) and similar \ncompared with the other active treatments \n3a. Hypoglycemia \nAs the definition of hypoglycaemia varied \nacross trials, we did not calculate a \npooled estimate for risk.  Only a few \nhypoglycaemias were observed in any \ntreatment arm in trials that compared a G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 37 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nDPP-4 inhibitor with metformin as mono-\ntherapy or with pioglitazone or a GLP-1 \nagonist as second line treatment. On the \ncontrary, in most trials comparing a DPP-\n4 inhibitor with sulfonylureas combined \nwith metformin the risk for hypoglycaemia \nwas higher in the group receiving a sul-\nfonylurea. Across all studies analysed, \nsevere hypoglycaemia (defined as an \nepisode that required the help of another \nperson) occurred in six patients receiving \na DPP-4 inhibitor (n=6.615). In the control \ngroups, one patient receiving metformin \nas monotherapy (n=1.647), 51 receiving a \nsulfonylurea (n=3873), one patient receiv-\ning a GLP-1 agonist (n=381), and none of \nthe 445 patients receiving pioglitazone \nexperienced at least one episode of \nsevere hypoglycaemia  \n3b. Other adverse events \nTreatment with a DPP-4 inhibitor resulted \nin lower discontinuation rate because of \nany adverse event compared with met-\nformin monotherapy (risk ratio 0.69, 0.51 \nto 0.94; I2=0%) or with a GLP-1 agonist \ncombined with metformin (0.40, -0.21 to \n0.76; I2=0%) Diarrhoea, vomiting, and \nnausea were also more common in pa-\ntients receiving metformin or a GLP-1 \nagonist than DPP-4 inhibitors. No differ-\nence in the incidence of gastrointestinal \nevents was evident between DPP-4 \ninhibitors and sulfonylureas or pioglita-\nzone. Overall, DPP-4 inhibitors were not \nassociated with an increased risk of G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 38 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nnasopharyngitis (1.06, 0.95 to 1.19; \nI2=0%), upper respiratory tract infection \n(1.0, 0.83 to 1.22; I2=20%), or urinary \ntract infection (0.86, 0.51 to 1.45; I2=64%) \ncompared with any of  the hypoglycaemic \ndrugs in the control groups. \nSystema-\ntischer \nReview \nund Meta-\nAnalyse McIntosh \nB. et al. \n(2011) \n[2] Suchzeitraum: \n1980 to October \n2009 \nQuellen: \nOnly English \nLanguage \nMEDLINE, EM-\nBASE, BIOSIS \nPreviews, Pub-\nMed and the \nCochrane Central \nRegister of Con-\ntrolled Trials \nAdditional cita-\ntions were ob-\ntained from grey \nliterature and \nconference  \nproceedings and \nthrough stake-\nholder feedback. \nTwo reviewers \nindependently \nselected studies, \nextracted data \nand assessed risk \nof bias. Interventionen: \nall available classes of \nantihyperglycemic \ntherapies in patients \nwith type 2 diabetes \ninadequately controlled \nby metformin monother-\napy. Mixedtreatment \ncomparison and pair-\nwise meta-analyses \nwere conducted to pool \ntrial results, when ap-\npropriate. \nThe following agents \nwere assessed: \nsulfonylureas, megliti-\nnides, thiazolidinedi-\nones, DPP-4 inhibitors, \nGLP-1 analogues, \ninsulins and insulin \nanalogues, alpha-\nglucosidase inhibitors \nand weight-loss agents \n(orlistat and sibu-\ntramine). \nEndpunkte: \nhemoglobin A1c, body Included studies: \n49 active and non-active controlled ran-\ndomized trials that compared 2 or more of \nthe following classes of antihyperglycemic \nagents and weight-loss agents: sulfonylu-\nreas, meglitinides, thiazolidinediones \n(TZDs), dipeptidyl peptidase-4 (DPP-4) \ninhibitors, glucagon-like peptide-1 (GLP-\n1) analogues, insulins, alpha-glucosidase \ninhibitors, sibutramine and orlistat. \nStudy characteristics and methodolog-\nical quality \nMost trials were 6\u201312 months long, alt-\nhough 1 study was over 5 years in dura-\ntion. Mean baseline HbA1c ranged from \n6.6% to 10% (weighted mean \u00b1 standard \ndeviation [SD] 8.0% \u00b1 0.9%). The base-\nline duration of diabetes ranged from 1.8 \nto 10.3 years (weighted mean \u00b1 SD 6.1 \u00b1 \n5.1 years). The inclusion threshold for \nbaseline HbA1c was typically 7.0%\u201310%; \nhowever, some studies used thresholds \nas low as 6.5% or as high as 11.5%. \nThere were also differences in the dura-\ntion and dosage of metformin monothera-\npy at baseline, although subjects used \u2265 \n1500 mg for \u2265 3 months in many studies. \nThree scenarios for treatment history    G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 39 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nStudien: \nRCT \nPatienten:  \npatients with type \n2 diabetes inade-\nquately controlled \nby metformin \nmonotherapy \nhemoglobin \n(HbA1c > 6.5%, \nfasting plasma \nglucose (FPG) > \n7 mmol/L or 2-\nhour postprandial \nglucose (PPG) > \n10 mmol/L) weight, hypoglycemia, \nquality of life,  long-term \ndiabetes-related compli-\ncations, serious adverse \ndrug events and mortali-\nty. before metformin monotherapy failure \nwere identified.  \nMost studies (89%) were industry funded. \nAbout two-thirds of the studies identified \nwere of poor methodological quality: \ninadequate allocation concealment, failure \nto use an intention-to-treat analysis and \nlack of blinding were common limitations. \nPublication bias was not assessed be-\ncause of a limited number of studies for \neach pairwise comparison \n1. Intermediate Outcomes \n1a. HbA1c/Glycemic Control \nForty RCTs (n = 17. 795) reported change \nfrom baseline in HbA1c. All classes of \nsecond-line antihyperglycemic therapies \nachieved clinically meaningful reductions \nin hemoglobin A1c (0.6% to 1.0%). No \nsignificant differences were found be-\ntween classes. Effect estimates ranged \nfrom \u22120.65% (95% confidence interval \n[CI] \u22121.14 to \u22120.20) for meglitinides to \n\u22120.96% (95% CI \u22121.57 to \u22120.38) for \nbiphasic insulins. \n1b. Weight \nAn increase in body weight was observed \nwith the majority of second-line therapies \n(1.8 to 3.0 kg), the exceptions being DPP-\n4 inhibitors, alpha-glucosidase inhibitors \nand GLP-1 analogues (0.6 to \u22121.8 kg). \n2. Longterm Outcomes \nThere were insufficient data available for \ndiabetes complications, mortality or quali-G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 40 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nty of life. \n3. Adverse Events \nInsulins and insulin secretagogues were \nassociated with significantly more events \nof overall hypoglycemia than the other \nagents, but severe hypoglycemia was \nrarely observed. \n4. Quality of life \nThere were insufficient data available for \ndiabetes complications, mortality or quali-\nty of life \nMeta-\nAnalysis Monami M \net al. \n(2010) \n[10] Medline search \nup to November \n11th, 2008 \nInclusion: \nRCTs, either \npublished or \nunpublished, \nperformed in type \n2 diabetic patients \nwith DPP-4 inhibi-\ntors, with a dura-\ntion >12 weeks  \nExclusion:  \nTrials with a \nshorter duration; \ntrials enrolling \nnondiabetic, or \ntype 1 diabetic \nsubjects Intervention=oral Dipep-\ntidyl Peptidase-4 (DPP-\n4) inhibitors sitagliptin \nand vildagliptin versus \nplacebo or active com-\nparators \n \nprimary outcome: effect \nof DPP-4 inhibitors, \ncompared with other \nhypoglycemic agents or \na placebo, on HbA1c  \nSecondary outcomes: \nBMI  \n 41 RCTs (9 of which are unpublished) \nwere included  \nResults: \non HbA1c: \n- similar efficacy in monotherapy and in \ncombination with other agents  \n- in placebo-controlled studies: non sign. \nreduction of HbA1c in unpublished \ntrials: (-0.68; CI  [-1.57; 0.21]; p=0.13) \n- in placebo-controlled studies: non sign.  \nreduction of HbA1c in published trials: -\n0.70;  CI [-0.80; -0.59]; p < 0.001 \n- in active-comparator studies: similar \neffect to that of thiazolidinediones; sul-\nfonylureas and metformin were more \neffective than DPP-4 inhibitors \non body weight:  \n- non sign. effect on BMI in placebo-\ncontrolled trials (+0.2 [-0.1; 0.6] kg/m2; \np=0.11; 13 trials) \n- significant difference in comparison Limitations:  \nsummary data, a time-to-\nevent analysis for categorial \noutcomes (including cardio-\nvascular events) could not be \nperformed; number of subject \nstudies and the duration of \ntrials performed is insufficient \nto draw any definitive conclu-\nsion on the long-term cardio-\nvascular safety  \nStudy quality: (Randomiza-\ntion/ Dropout rate/ intention-\nto-treat): \n- Description of randomiza-\ntion: 4- adequate reported, \n37-not adequate reported \n- intention-to-treat analysis: 2 \n\u2013no, 2-not reported, 37 - \nyes  \n- numbers of withdrawals, Pan C, et al. Diabet Med \n2008; \nRosenstock J, et al. \nDiabetes Care 2007; \nRosenstock J, et al. \nDiabetes Obes Metab \n2007; \nDejager S, et al. Horm \nMetab Res 2007; \nScherbaum WA, et al. \nDiabetes Obes Metab \n2008. \nMari A, et al. J Clin \nEndocrinol Metab 2008;. \nScherbaum WA, et al. \nDiabetes Obes Metab \n2008; \nPi-Sunyer FX, et al. \nDiabetes Res Clin Pract \n2007; \nRistic S, et al. Diabetes 1+ G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 41 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nwith thiazolidinediones (-0.2; [-0.3;-0.1] \nkg/m2; p=0.008) \nadverse events/safety: \n- hypoglycemia: \n- low risk of hypoglycemia : incidence \nwas not significantly different from pla-\ncebo ; significantly lower hypoglycemic \nrisk than sulphonylureas, no significant \ndifferences to thiazolidinediones \n- others : \n- no association with any increase in the \noverall risk of adverse events in com-\nparison with placebo (Mantel-Hensel \n(MH)-OR 1.03 [0.93; 1.13]; p=0.51) or \nthiazolidinediones (0.97 [0.81; 1.17]; \np=0.75, N=5 trials) ; the incidence was \nsignificantly lower than with sulphonylu-\nreas (0.64 [0.51; 0.80]; p < 0.001, N=2 \ntrials), metformin (0.78 [0.61; 1.00]; \np=0.050, N=2 trials), and a-glucosidase \ninhibitors (0.51 [0.39; 0.67]; p < 0.001, \nN=2 trials) \n- risk of cardiovascular events: 0.76 \n[0.46-1.28]; p=0.30 (in comparison with \nplacebo controlled groups : 0.86 [0.47-\n1.59], p=0.63) \n- risk of all-cause death compared with \ncontrol groups : 0.78 [0.40-1.51], \np=0.47 \nAuthors Conclusion:  \nDPP-4 inhibitors reduce HbA1c, although \nto a lesser extent than sulphonylureas, \nwith no weight gain and no hypoglycemic reasons for withdrawal or \ndropout-adequate repor-\nting: 1-no, 7-no reported, \n33- adequate reported \n- Description of blinding: 9-\nadequate reported, 32-not \nadequate reported \n- Quality assessment: Jadad \nscore was used  \nHeterogeneity: \n- Random and fixed effects \nmodel, results of random \neffect model were reported   \n- Significant heterogeneity: \nI2 for heterogeneity on \nHbA1c was 94.6 (p < 0.01) \nPublication bias: \n- The Begg adjusted rank \ncorrelation test (Kendall \ntau:-74; p=0.13) and the \nEgger regression approach \n(intercept, -2.81 [CI, -6.91; -\n1.27]) suggested no major \npublication bias Obes Metab 2005; \nAhren B, et al. Diabetes \nCare 2005; \nGarber AJ, et al. \nDiabetes Obes Metab \n2007; \nD\u2019Alessio DA, et al. J \nClin Endocrinol Metab \n2008. \nScott R, et al. Diabetes \nObes Metab 2008; \nNonaka K, et al. \nDiabetes Res Clin Pract \n2008; \nRaz I, et al. Diabetologia \n2006; \nCharbonnel B, et al. \nDiabetes Care 2006; \nAschner P, et al. \nDiabetes Care 2006; \nRaz I, et al. Curr Med \nRes Opin 2008; \nRosenstock J, et al. \nDiabetes Obes Metab \n2008; \nNovartis website 2008,  \nMerck website 2008,  \nHanefeld M, et al. Curr \nMed Res Opin 2007; \nNauck MA, et al. \nDiabetes Obes Metab G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 42 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nrisk  2007; \nScott R, et al. Int J Clin \nPract 2007; \nGarber AJ, et al. \nDiabetes Obes Metab \n2008. \nFonseca V, et al. \nDiabetologia 2007; \nBolli G, et al. Diabetes \nObes Metab 2008; \nBosi E, et al. Diabetes \nCare 2007; \nGoldstein BJ, et al. \nDiabetes Care 2007; \nHermansen K, et al. \nDiabetes Obes Metab \n2007; \nPratley RE, et al. Horm \nMetab Res 2006; \nSchweizer A, et al. \nDiabet Med 2007; \nMeta-\nAnalysis Vilsb\u00f8ll T \net al. \n(2012) \n[11] Electronic \nsearches (Co-\nchrane Library, \nMedline, Embase, \nand Web of \nScience) and \nmanual searches \n(up to May 2011) \nInclusion:   \nRCT of adults \nwith or without Intervention:  \nexenatide twice daily \n(n=13 trials), liraglutide \n(n=8), and exenatide \nonce weekly (n=4); 3 \ntrials compared directly \nexenatide twice daily \nwith liraglutide or with \nexenatide once weekly; \ndose of liraglutide in \nmost trials was 1.2 or Included studies: 25 RCTs \nResults: \n- For weight loss (3395 participants with \nGLP-1R agonists and 3016 in control \ngroups, 21 trials):  \n- mean reduction in body weight \nwith the highest dose of GLP-1R \nagonists ranged from \u20137.2 to \u20130.2 \nkg.  \n- In GLP-1R agonist groups: greater \nweight loss than control groups Strenght/Limitations: \n- internal validity, but all the \nincluded trials received in-\ndustry funding \nStudy quality: (Randomiza-\ntion/ Dropout rate/ intention-\nto-treat): \n- random allocation: ade-\nquate in all trials  \n- allocation concealment: Astrup A, et al. Lancet \n2009; \nElkind-Hirsch K, et al. J \nClin Endocrinol Metab \n2008; \nRosenstock J, et al. \nDiabetes Care 2010; \nApovian CM, et al. Am J \nMed 2010; \nBergenstal R, et al. Curr 1+ G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 43 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \ntype 2 diabetes \nand who had BMI \nof 25 or more;  \nIntervention:  \nGLP-1R agonist \n(exenatide given \ntwice daily, \nexenatide given \nonce weekly (as a \nlong acting re-\nlease), and li-\nraglutide given \nonce daily) in \nclinically relevant \ndoses (at least 10 \n\u03bcg/day for exena-\ntide (5 \u03bc g twice \ndaily), 2 mg/week \nfor exenatide \nonce weekly, and \n1.2 mg/day for \nliraglutide once \ndaily) versus \ncontrol group: \nplacebo, no \nintervention, or \nantidiabetic drugs \nIf trials included \nmore than one \ncontrol group, \ndata from the \nmost weight \nneutral interven-\ntion (for example, \nplacebo instead of 1.8 mg/day; in one trial - \nof 2.4 and 3 mg/day; \ndoses of exenatide were \n10 to 20 \u03bc g/day or 2 \nmg/week. \ncontrol groups  recei-\nved placebo, third \ngeneration sulphonylu-\nrea compounds, insulin, \ndipeptidyl peptidase 4 \ninhibitors, thiazolidine-\ndiones, or metformin. In \ntrials of patients with \ntype 2 diabetes, cointer-\nventions given to the \nintervention and control \ngroup included metfor-\nmin, sulphonylurea \ncompounds, or thiazoli-\ndinediones. \nMain outcome:   \nweight loss (weighted mean difference \u22122.9 \nkg, 95% CI \u20133.6 to \u20132.2; 21 trials, \n6411 participants)  \n- Subgroup analyses: \n- weight loss in the GLP-1R agonist \ngroups for patients without \ndiabetes (\u20133.2 kg, CI \u20134.3 to\u20132.1; \nthree trials)  \n- weight loss in the GLP-1R agonist \ngroups for patients with diabetes \n(\u20132.8 kg, CI  \u20133.4 to \u20132.3; 18 \ntrials).  \n- no difference in body weight changes \nfor liraglutide versus exenatide twice \ndaily (\u22120.4 kg, 95% CI \u20131.3 to 0.6), or \nfor exenatide as a long acting release \nversus exenatide twice daily (\u20130.6 kg, \u2013\n1.5 to 0.3).  \n- weight reduction in trials assessing \nexenatide twice daily (\u20132.8 kg, \u20132.9 to \n\u20132.7), exenatide once weekly (\u20132.8 kg, \n\u20135.2 to \u20130.3), and liraglutide (\u20132.2 kg, \u2013\n3.5 to \u20130.9).  \n- weight reduction for trials with placebo \n(\u20131.9 kg, \u20132.9 to \u20130.9; 10 trials), insulin \n(\u20134.8 kg, \u20135.1 to \u20134.5; six trials), oral \nantidiabetic drugs including metformin \nor sulphonylurea compounds (\u20133.0 kg, \n\u20134.9 to \u20131.2; three trials), and dipep-\ntidyl peptidase 4 inhibitors (\u20132.0 kg, \u2013\n2.9 to \u20131.1; two trials).  \n- For secondary outcomes:  \n- beneficial effects of GLP-1R ago-\nnists on systolic and diastolic adequate in all trials \n- intention-to-treat analysis in \nall trials   \n- numbers of withdrawals, \nreasons for withdrawal or \ndropout \n- patient characteristics at \nbaseline and the diagnostic \ncriteria for type 2 diabetes \nwere very similar across \ntrials; baseline treatment \nand control groups were \nbalanced \n- Blinding: 13 trials were \ndouble blind, none of  in-\ncluded trials reported the \nsuccess of blinding \n- All trials reported clinically \nrelevant outcome \nmeasures, provided a clear \ndescription of losses to fol-\nlow-up, accounted for pa-\ntients with missing data in \nthe analyses, and under-\ntook sample size calcula-\ntions.  \n- None of the trials were \nterminated prematurely. \n- no evidence of reporting \nbias when comparing pub-\nlished trial protocols with \nsubsequent trial reports \nwas founded Med Res Opin 2009; \nBergenstal RM, et al. \nLancet 2010; \nBlevins T, et al. J Clin \nEndocrinol Metab 2011; \nBunck MC, et al. \nDiabetes Care 2009; \nBuse JB, et al. Diabetes \nCare 2004; \nBuse JB, et al. Lancet \n2009; \nDavis SN, et al. \nDiabetes Care 2007; \nDeFronzo RA, et al. \nDiabetes Care 2010; \nDerosa G, et al. \nDiabetes Technol Ther \n2010; \nDiamant M, et al. Lancet \n2010; \nDrucker DJ, et al. Lan-\ncet 2008; \nGarber A, et al. Lancet \n2009; \nHeine RJ, et al. Ann \nIntern Med 2005; \nKendall DM, et al. \nDiabetes Care 2005; \nMarre M, et al. Diabet \nMed 2009; \nMoretto TJ, et al. Clin G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 44 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \ninsulin) were \nincluded. Rando-\nmised compari-\nsons between \nexenatide and \nliraglutide were \nincluded. Duration \nof at least 20 \nweeks that as-\nsessed clinically \nrelevant doses \n(see \u201cinterven-\ntion\u201d). blood pressure, plasma concen-\ntrations of cholesterol, and gly-\ncaemic control; not significant ef-\nfect on plasma concentrations of \nliver enzymes. GLP-1R agonists \nwere associated with nausea, \ndiarrhoea, and vomiting, but not \nwith hypoglycaemia. \nDescriptive statistics: \n- All trials were multicentred (mean \nnumber of clinical sites 68) and multi-\nnational.  \n- Most trials were done in the US and \nEurope.  \n- duration of individual trials ranged from \n20 to 52 weeks.  \n- 3 trials included patients without \ndiabetes, remaining trials - with type 2 \ndiabetes \n- Mean BMI ranged from 29 to 41, and \nmean weight from 82 to 111 kg \n- For patients with type 2 diabetes: mean \nconcentration of fasting plasma glu-\ncose at baseline ranged from 8.0 to \n11.7 mmol/L for GLP-1R agonist \ngroups, and from 8.2 to 11.2 mmol/L \nfor control groups; mean values of \nHbA1c at baseline ranged from 7.6% to \n10.4% for GLP-1R agonists and 7.4% \nto 10.3% for controls. \nAuthor conclusions:  \nevidence that treatment with GLP-1R \nagonists leads to weight loss in Heterogeneity: \n- Both random and fixed \neffects model were used   \n- I2 tests  \n- Heterogeneity: evidence of \nintertrial heterogeneity \n(tau2=2.4, P<0.01), but no \nevidence of bias or small \nstudy effects in regression \nanalyses.  \n- Random effects meta-\nregression of the primary \nmeta-analysis found that \nBMI at baseline and trial \nduration did not predict the \nsize of the estimated inter-\nvention or explain intertrial \nheterogeneity (P=0.293 \nand P=0.284). \nPublication bias: \n- See \u201cStudy quality\u201d Ther 2008; \nNauck M, et al. Diabetes \nCare 2009; \nNauck MA, et al. \nDiabetologia 2007; \nPratley RE, et al. Lancet \n2010; \nRussell-Jones D, et al. \nDiabetologia 2009; \nZinman B, et al. \nDiabetes Care 2009; G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 45 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \noverweight or obese patients with or \nwithout type 2 diabetes mellitus \nMeta-\nAnalysis Hirst JA et \nal. (2012) \n[12] MEDLINE, EM-\nBASE, and the \nCochrane Central \nRegister of Con-\ntrolled Trials were \nsearched from \n1950 to June \n2010 \nInclusion crite-\nria: \n1) RCT  2) parti-\ncipants with \ndiabetes; 3) \nfollow-up of at \nleast 12 weeks; 4) \ntreatment group \nof metformin \nmonotherapy, or \nmetformin as an \nadd-on therapy; \n5) placebo or \nbackground \ntreatment compa-\nrator group; 6) \nrandomize pa-\ntients to a fixed \ndose of metfor-\nmin; 7) blind \npatients to oral \nmedications; 8) \nuse the same Outcome measures: \nchange in HbA1c levels \nfrom baseline to the end \nof the trial, total adverse \nevents, and gastric \nadverse events \n(diarrhea and abdominal \ncramps).  Included trials: 35 RCTs (7 \u2013 for compari-\nson analysis) = 7,960 participants \nResults: \n- Metformin monotherapy versus place-\nbo lowered HbA1c by 1.12% (95% CI \n0.92\u20131.32, P<0.00001)= reduction of \n12 mmol/mol more with metformin than \nplacebo;  in 10 trials with > or = 24 \nweeks HbA1c was 1.19% lower (CI \n0.98\u20131.41) in metformin groups  \n- metformin+ oral therapy versus place-\nbo+oral therapy lowered HbA1c by \n0.95% (CI 0.77\u20131.13, P<0.00001) = \nreduction of 11mmol/mol more with \nmetformin than in the comparator \ngroup; in 11 trials with > or = 24 weeks \nHbA1c was 0.94% lower (0.76\u20131.13; I2 \n= 78.6%) in the metformin groups  \n- metformin+ insulin therapy versus \ninsulin only lowered HbA1c by 0.60% \n(95% CI 0.30\u20130.91; P = 0.0001) = re-\nduction of 6 mmol/mol more in the \nmetformin groups \n- significantly greater reduction in HbA1c \nusing higher doses of metformin (re-\nduction in HbA1c of 0.26% (95% CI \n0.14\u20130.38; P , 0.0001) compared with \nlower doses of metformin with no signi-\nficant increase in side effects \n- number of adverse events: most com-\nmonly =gastrointestinal events, but al-Study quality: (Randomiza-\ntion/ Dropout rate/ intention-\nto-treat): \n- only 8 stated the method of \nrandomization  \n- intention-to-treat analysis n. \na.   \n- numbers of withdrawals, \nreasons for withdrawal or \ndropout n.a.  \n- Blinding: All of the included \ntrials were double blinded, \nwith the exception of one \ntrial = partially blinded \nHeterogeneity: \n- random/fixed effects model  \n- I2 tests (HbA1c): for \nMetformin monotherapy I2 \n= 80,2 %, for metformin \nadded to oral therapy I2 = \n77.1 %, for metformin+ in-\nsulin therapy I2 = 79.8%; \nfor adverse events see re-\nsults \n- Sign. heterogeneity \n(p=0.000) \n- no single factor could ex-\nplain the heterogeneity was \nfounded \nPublication bias: (reported in supplemen-\ntary data)  \nAvil\u00e9s-Santa L, et al. \nAnn Intern Med.1999 \nAug 3;131(3):182-8. \nBosi E, et al. Diabetes \nObes Metab. 2009 \nMay;11(5):506-15. \nChiasson JL, et sl.  \nDiabetes Care. 2001 \nJun;24(6):989-94. \nDamsbo P, et al. \nDiabetes Care. 1998 \nSep;21(9):1489-94. \nDeFronzo RA, et al. N \nEngl J Med. 1995 Aug \n31;333(9):541-9. \nDerosa G, et al. Metabo-\nlism. 2009 \nAug;58(8):1059-66. \nDouek IF, et al .Diabet \nMed. 2005 \nMay;22(5):634-40. \nFujioka K, et al. \nDiabetes Obes Metab. \n2005 Jan;7(1):28-39. \nGarber AJ, et al. Am J \nMed. 1997 \nDec;103(6):491-7. 1- G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 46 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nmetformin dose \nfor each patient in \nthe trial; and 9) \nuse the same \nfixed dose of any \nother oral glu-\ncose-lowering \nmedication used \nin combination \nwith metformin in \nboth the metfor-\nmin and compara-\ntor arms. so hypoglycemia, dizziness, headache, \nurinary tract infection, hypertension, \ncoughing, and palpitations; \n- increased in metformin-treated groups \nin the monotherapy trials (RR 1.13 \n[95% CI 1.06\u20131.21]; I2 = 3%, P \n=0.0003), and in oral combination trials \n(RR 1.03 [0.95\u20131.12]; I2 = 82%, P = \n0.45) \n- in insulin trials=not significantly diffe-\nrent between the metformin group and \nthe comparator group (2.37 [0.65\u2013\n8.67]; I2 = 73%, P =0.19) \nDescriptive statistics: \n- 15 trials with metformin monotherapy \ncompared with placebo, no treatment, \nor diet (2,424 participants); 12 metfor-\nmin treatment in combination with ano-\nther oral antihyperglycemic medication \ncompared with the other medication \n(4,511 participants); and 13 - metformin \nin combination with insulin treatment \ncompared with patients on insulin \ntreatment only (1,025 participants) \n- Five trials with multiple arms  \nAuthors conclusion:  \nEvidence supports the effectiveness of \nmetformin therapy in a clinically important \nlowering of HbA1c used as monotherapy \nand in combination with other therapeutic \nagents. There is potential for using higher \ndoses of metformin to maximize glycemic \ncontrol in diabetic patients without increa-- N.a. Giugliano D, et al. Eur J \nClin Pharmacol. \n1993;44(2):107-12. \nGoldstein BJ, et al. \nDiabetes Care. 2007 \nAug;30(8):1979-87. \nGrant PJ. Diabetes \nCare. 1996 \nJan;19(1):64-6. \nH\u00e4llsten K, et al. \nDiabetes. 2002 \nDec;51(12):3479-85. \nHermann LS, et al. \nDiabetes Obes Metab. \n2001 Dec;3(6):428-34. \nHoffmann J, et al. Am J \nMed. 1997 \nDec;103(6):483-90. \nHorton ES, et al \n.Diabetes Care. 2000 \nNov;23(11):1660-5. \nIozzo P, et al Diabetes \nCare. 2003 \nJul;26(7):2069-74. \nJacobsen IB, et al \n.Basic Clin Pharmacol \nToxicol. 2009 \nSep;105(3):145-9. \nJadzinsky M, et al \n.Diabetes Obes Metab. \n2009 Jun;11(6):611-22. \nKhan AS, et al. Diabet \nMed. 2006 G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 47 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nsing gastrointestinal effects. Oct;23(10):1079-84. \nLewin A, et al Clin Ther. \n2007 May;29(5):844-55. \nList JF, et al Diabetes \nCare. 2009 \nApr;32(4):650-7. \nLund SS, et sl .PLoS \nOne. 2008;3(10):e3363. \nMeyer L, et al. Diabetes \nCare. 2002 \nDec;25(12):2153-8. \nMoses R, et al. Diabetes \nCare. 1999 \nJan;22(1):119-24. \nNatali A, et al. Diabetes \nCare. 2004 \nJun;27(6):1349-57. \nPerez A, et al. Curr Med \nRes Opin. 2009 \nDec;25(12):2915-23. \nPonssen HH, et al. Clin \nTher. 2000 \nJun;22(6):709-18. \nRobinson AC, et al . \nDiabetes Care. 1998 \nMay;21(5):701-5. \nRyysy L, et al. Diabetes \nCare. 2001 \nMar;24(3):549-54. \nViljanen AP, et al .J Clin \nEndocrinol Metab. 2005 \nDec;90(12):6523-8. G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 48 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nWilliams-Herman D, et \nal. Curr Med Res Opin. \n2009 Mar;25(3):569-83. \nWolever TMS, et al. Nutr \nRes. 2000;20(10):1447-\n56 \nWulffel\u00e9 MG, et al \n.Diabetes Care. 2002 \nDec; 25 (12):2133-40. \nYki-J\u00e4rvinen H, et al \n.Ann Intern Med. 1999 \nMar 2;130(5):389-96. \nMeta-\nAnalysis Lamanna \nC. et al. \n(2011) \n[13] \n MEDLINE, EM-\nBASE, and the \nCochrane Central \nRegister of Con-\ntrolled Trials were \nsearched up to  \n31 October 2009 \nInclusion crite-\nria: \nRCT comparing \nmetformin, it \nplacebo, active \nglucose-lowering \ntherapies or no \ntherapy, duration \n>/= 52 week, \nconcurrent thera-\npies were not \ndifferent in \nmetformin and \ncomparator arms, Main outcomes: \ncardiovascular morbidity \nand mortality in patients \ntreated with metformin  Included studies: 35 RCTs  \nResults: \n- On cardiovascular events (12 RCTs, \n5455 patients with metformin and 8996 \n\u2013 in comparator group, non-diabetic \nand diabetic patients):  \n- Overall - no sign. effects on cardi-\novascular events   \n- Sign. reduction of cardiovascular \nevents in comparison with placebo \nor -no therapy  \n- in comparison with rosiglitazone (2 \nRCTs): OR for major cardiovascu-\nlar events in patients with metfor-\nmin: 1.06 (95 % CI 0.87-1.28, \np=0.57) \n- No significant effect of metformin \non the incidence of myocardial in-\nfarction, stroke or heart failure \n(MH-OR 0.90 [0.71 1.14], 0.92 \n[0.65-1.29], 1.12 [0.25-9.04]), all Study quality: (Randomiza-\ntion/ Dropout rate/ intention-\nto-treat): \n- random allocation: in 21 \nRCTs not adequate \n- allocation concealment: : in \n21 RCTs not adequate \n- intention-to-treat analysis: \nonly in 17 RCTs - yes   \n- numbers of withdrawals, \nreasons for withdrawal or \ndropout: n.a.  \n- baseline treatment and \ncontrol groups were bal-\nanced: n.a.  \n- Blinding: in 22 RCTs not \nadequate \n- PRISMA Checklist and \nJadad score for quality \nassestment were used UK Prospective \nDiabetes Study \n(UKPD5Lancet 1998; \n352: 854~865. \nSelvin Eet al. Arch \nIntern Med 2008  \nReferences im Appen-\ndix: \nHermann LS, et al \n.Diabetes Obes Metab. \n2001; 3(6):428-34. \nYki-J\u00e4rvinen H et al \n1999 Mar 2;130(5):389-\n96 \nCampbell IW, et al  \nDiabete Metab. 1994 \nJul-Aug;20(4):394-400. \nKlein W. Diabete Metab. \n1991 May;17(1 Pt \n2):235-40. 1- G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 49 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \ntrials in which \ncardiovascular \nevents were a \npre-defined end-\npoint together \nwith trials de-\nsigned for other \n(mainly metabolic) \nendpoints; \nStudies with no \nevents were \nexcluded  p<0.35 \n- On all cause and cardiovascular mor-\ntality:  \n- 5 RCTs with at least one event: -\nno effect on  all  cause mortality  \n- signitkant increase of mortality - in \nthe 2 trial with metfor-\nmin+sulphonylureas \n- Similar results for cardiovascular \nmortality: MH-OR in 5 trials was \n0.923 [0.361-2.320], (p = 0.86);  \n- signiticant reduction of mortality in \n4 RCTs with metformin monother-\napy (MH-OR 0.554 [0.356-0.890], \np=0.014) \n- meta-regression: more beneficial \neffect on all-cause mortality in tri-\nals of longer duration (Intercept: \n0.612[0.138-1.087]: Slope: -\n0.002[-0.003 to -0.00004[, p = \n0.008 ), and with higher proportion \nof women (Intercept: 2.237[0.184-\n4.290]; Slope: -0.039[-0.076 to -\n0.003[, p = 0.034)   \nDescriptive statistics: \n- in total, 7171 participants with metfor-\nmin and 11301 participants with com-\nparator were included  \n- 451 cardiovascular events in metformin \ngroup and 775 \u2013 in comparator group  \n- Median duration was 112 weeks (range \n52-343 weeks)  \n-8 trials did non describe cardiovascu-- Power analysis \u2013 90%   \nHeterogeneity: \n- Both random and fixed \neffects model, results of \nrandom effects model were \nreported   \n- I2 tests  \n- Heterogeneity: not signifi-\ncant (p=0.46, Q=10.08)  \nPublication bias: \n- Was assessed (Funnel \nplot, Eggers test)  \n- No evidence for publication \nbias (p=0.46) V\u00e4h\u00e4talo M, et al Scand \nJ Prim Health Care. \n2007 Sep;25(3):147-53 \nYamanouchi T et al \nDiabet Med. 2005 \nAug;22(8):980-5. \nDouek IF, et al Diabet \nMed. 2005 \nMay;22(5):634-40 \nSchweizer A, et al \nDiabet Med. 2007 \nSep;24(9):955-61. Epub \n2007 Schernthaner G, \net al Clin Endocrinol \nMetab. 2004 \nDec;89(12):6068-76 \nDerosa G, et al Metabo-\nlism. 2009 \nAug;58(8):1059-66. \nEpub 2009 Gregorio F, \net al  Diabet Med. 1999 \nDec;16(12):1016-24. \nTeupe B, et al Diabete \nMetab. 1991 May;17(1 \nPt 2):213-7 \nCharbonnel B, et al \nDiabetologia. 2005 \nJun;48(6):1093-104. \nEpub 2005 Barnett AH \net al  Int J Clin Pract. \n2007 Oct;61(10):1614-\n25. Erratum in: Int J Clin \nPract. 2008 G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 50 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nkar events \nAuthors conclusion:  \nAvailable evidence seems to exclude any \noverall harmful effect of metformin  on \ncardiovascular risk, suggesting a possible \nbenefit versus placebo/no treatment. \n Jan;62(1):171 \nMaji D, et al. J Indian \nMed Assoc. 2005 \nNov;103(11):609-11. \nKahn SE, et al. N Engl J \nMed. 2006 Dec \n7;355(23):2427-43. \nEpub 2006 Dec 4. \nErratum in: N Engl J \nMed. 2007 Mar \n29;356(13):1387-8.  \nKooy A, et al.  Arch \nIntern Med. 2009 Mar \n23;169(6):616-25 \nPalomba S, et al. J Clin \nEndocrinol Metab. 2007 \nAug;92(8):3128-35. \nEpub 2007 May 22. \nIbanez L, et al. J Pediatr \n2004;144:23-29. \nHarborne L, et al. J Clin \nEndocrinol Metab. 2003 \nSep;88(9):4116-23. \nTomazic J, et al. Acta \nDermatovenerol Alp \nPanonica Adriat. \n2005;14:99-105. \nLi CL, et al. Diabet Med. \n1999 Jun;16(6):477-81. \nMart\u00ednez E, et al. Antivir \nTher. 2003 \nOct;8(5):403-10. \nGambineri A, et al. J G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 51 \nStudien-\ntyp Quelle Untersuchte \nStudien (verglichene) Inter-\nventionen/ \n(ggf. Dosierung) Ergebnisse  Bemerkungen Literaturbelege Eviden-\nzniveau \n(SIGN) \nClin Endocrinol Metab. \n2006 Oct;91(10):3970-\n80. Epub 2006 Jul 25. \nLund SS, et al. PLoS \nOne. 2008;3(10):e3363. \nEpub 2008 Oct 9. \nCharles MA, et al. \nDiabetes Care. 1998 \nNov;21(11):1967-72 \nZhang JL, et al.  Am J \nHypertens. 2009 \nAug;22(8):884-90. Epub \n2009 Stakos DA, et al. \nHeart. 2005 \nMay;91(5):589-94. \nSchuster D, et al. \nDiabetes Care. 2004 \nNov;27(11):2768-\n9.Abstract n.a.  \nRamachandran A, et al. \nDiabetologia. 2006 \nFeb;49(2):289-97. Epub \n2006  \nIb\u00e1\u00f1ez L, et al. J Clin \nEndocrinol Metab. 2008 \nMay;93(5):1841-5. Epub \n2008 Mar 4. \n \n  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 52 \nEinzelstudien  \nQuelle/ \nStudientyp Population (verglichene) Interven-\ntionen/ \nggf. Dosierung/ \nggf. Follow-up Outcomes Ergebnisse Bemerkungen Eviden-\nzniveau \n(SIGN/ \nCEBM \nOxford) \nORIGIN Trial \nInvestigators \n(2012) \n[14] \n \nRCT \n Total of population  \n(n =  12537) \nPat. characteristics:  \nMean age 63.5 years \nwith cardiovascular \nrisk factors and Type II \ndiabetes or impaired \nglucose tolerance \nInclusion criteria:  \nParticipants > 50 \nyears with a prior CV \nevent (myocardial \ninfarction, stroke, or \nrevascularization); \nangina with docu-\nmented ischaemia; \nalbuminuria; left ven-\ntricular hypertrophy; \nangiographic evidence \nof > 50% stenosis of a \ncoronary, carotid, or \nlower extremity artery; \nor an ankle/brachial \nindex < 0.9 were \nrecruited if they also \nhad a history of type 2 \ndiabetes that was \nstable on 0 or 1 oral \nglucose lowering \nagents; or IFG, IGT or Glargine versus standard \ncare: \ninsulin glargine added an \nevening injection to their \nglycemic-control regimen \n(glimepiride, metformin, \nrapid-acting insulin were \npermitted) versus standard \ncare on the basis of the \ninvestigator\u2019s best judgment \nand local guidelines (it was \npermitted to use any glu-\ncose lowering agent apart \nfrom insulin glargine. Pat. \nwere also advised to avoid \ninsulin until maximal doses \nof 2 different oral glucose \nlowering agents were requi-\nred). \nMedian follow-up was 6.2 \nyears. \n(2-by-2 factorial design with \nn-3-fatty acid vs. placebo, \nnot reported here) Two coprimary composite \noutcomes: \n# death from cardiovascular \ncauses, nonfatal myocardial \ninfarction, or nonfatal stroke, \n# composite of any of these \nevents plus revascularization \nprocedure (cardiac, carotid, or \nperipheral), or hospitalization \nfor heart failure. \nSecondary outcomes: \nOther adjudicated outcomes \nwere a composite microvascu-\nlar outcome, incident cases of \ndiabetes in participants wi-\nthout baseline diabetes, all-\ncause mortality and new or \nrecurrent cancers. \nHypoglycemic episodes and \nweight were also recorded. primary outcomes: \n- 1. hazard ratios of 1.02 (95% \nconfidence interval [CI], 0.94 \nto 1.11; P = 0.63) \n- 2. HR 1.04 (95% CI, 0.97 to \n1.11; P = 0.27) \nSecondary outcomes: \n- no significant difference in \nmortality (hazard ratio, 0.98; \n95% CI, 0.90 to 1.08; P = \n0.70) or microvascular events \n(hazard ratio, 0.97; 95% CI, \n0.90 to 1.05; P = 0.43). \n- no significant difference in \neach  component of the two \ncoprimary outcomes  or in the \nincidence of any cancer \n(hazard ratio, 1.00; 95% CI, \n0.88 to 1.13; P = 0.97), death \nfrom cancer (hazard ratio, \n0.94; 95% CI, 0.77 to 1.15; P \n= 0.52) \n- Severe Hypoglycemia 1% vs. \n0.31 %, p<0.001 \n- Weight: +1.6 kg vs. -0.5 kg \n- HbA1c: 6.2 % vs. 6.5% (Me-\ndian in yr 7 after baseline) Flowchart: yes suppl. appendix \nITT: yes \nRandomization not described in \ndetail \nBlinding: No \nGroups comparable/ similar: yes \nCOI: yes suppl.  \nPower calculation: yes, but adjusted \nby extension of the trial for 2 years \nThe overall type I error rate of 5% \nfor the two coprimary outcomes was \npartitioned such that the first co-\nprimary outcome was tested at a P \nvalue of 0.044 and the second \ncoprimary outcome was tested at a \nP value of 0.01 \nsupplementary table S 1: 1212 pat. \nhad stopped glarigin, reason \nstopped glargin adherence were  \n90.3% \u00abRefusal \u00bb without details \nmentioned. At this time, 80% were \nusing any insulin, 35% were not \nusing any oral glucose-lowering \nagents, and 47% were using \nmetformin. \nFew participants in the standard-\ncare group used insulin during the \ntrial - by the end of the study, 11% 1(+) G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 53 \nQuelle/ \nStudientyp Population (verglichene) Interven-\ntionen/ \nggf. Dosierung/ \nggf. Follow-up Outcomes Ergebnisse Bemerkungen Eviden-\nzniveau \n(SIGN/ \nCEBM \nOxford) \nnewly detected \ndiabetes based on \neither a FPG \u2265 6.1 \nmmol/L [110 mg/dL] or \na 2 hour plasma \nglucose \u2265 7.8 mmol/L \n[140 mg/dL] after a 75 \ng oral glucose load. \nExclsuion criteria:  \nunwillingess or an \ninability to inject insu-\nlin or do capillary \nglucose self-testing, a \nclear indication for, or \nintolerance to insulin \nor omega 3 fatty acids, \nunwillingness to stop \nthiazolidinediones if \nallocated to glargine, \nheart failure, coronary \nartery bypass surgery \nwithin the prior 4 years \nwith no intervening CV \nevent, or cancer \naffecting survival.  AEs: described \nCI: described Funding, regulatory \nsupport, site monitoring, drug distri-\nbution, and insulin glargine (Lantus) \nwere provided by Sanofi \nGallwitz  et al. \n(2012) \n[15] \n \nRCT \u2013 non-\ninferiority-Total of population  (n \n=  1029, 515/514 each \ngroup) multicentered \nat 128 centres in 14 \ncountries recruited \nbetween Sept 5, 2006, \nand March 29, 2011. Exenatide twice daily versus  \nglimepiride once daily as \nadd-on to metformin \n(Exenatide injected subcu-\ntaneously within 60 min \nbefore breakfast and eve-\nning meals, starting at 5 \u03bcg primary outcome: \ntime to inadequate glycaemic \ncontrol and need for alterna-\ntive treatment, defined as an \nHbA1c concentration of more \nthan 9% after the first 3 mon-\nths of treatment, or more than primary outcome:  \nMedian time to inadequate \nHbA1c control was 180 weeks \nwith exenatide versus 142\u00b71 \nweeks (52\u00b73) with glimepiride \n(p=0\u00b7032). \n203 (41%) of 490 patients in the ITT  was stated, but per-protocol- \nanalysis was done \uf0e0 They ran-\ndomly assigned 515 patients to the \nexenatide group and 514 to the \nglimepiride group, but only 490, \nresp. 487 Pat. were analysed. \nIn the exenatide group 174 disconti-1- G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 54 \nQuelle/ \nStudientyp Population (verglichene) Interven-\ntionen/ \nggf. Dosierung/ \nggf. Follow-up Outcomes Ergebnisse Bemerkungen Eviden-\nzniveau \n(SIGN/ \nCEBM \nOxford) \nstudy Pat. characteristics:  \nPatients aged 18\u201385 \nyears with type 2 \ndiabetes inadequately \ntreated by metformin. \nInclusion and exclu-\nsion criteria:  \nEligible participants \nhad type 2 diabetes; \nwere overweight to \nobese (body-mass \nindex [BMI] \u2265 25 kg/m\u00b2 \nto <40 kg/m\u00b2); aged \n18\u201385 years; had \nbeen on stable, maxi-\nmum tolerated doses \nof metformin; and had \ndeveloped subopti-\nmum glycaemic con-\ntrol, defi ned by a \nglycated haemoglobin  \n(HbA1c) concentration \nof 6\u00b75% and more or \n9\u00b70% and less. \nExclusion criteria were \ncontraindications for \nmetformin or limepi-\nride, according to the \nproduct-specifi c label; \nactive or untreated \nmalignancy or remis-\nsion for less than 5 twice daily for 4 weeks, \nfollowed by 10 \u03bcg twice \ndaily for the remaining study \nperiod.  \nStarting dose for patients in \nthe glimepiride group was 1 \nmg per day, adjusted every \n4 weeks, according to \ntolerability, up to the maxi-\nmum tolerated dose. \nConcomitant metformin was \ncontinued throughout the \nstudy for all patients, in the \nsame form and at the same \ndose as used at study entry. \n 7% at two consecutive visits \nafter the first 6 months. \nSecondary outcomes were \nmarkers of \u03b2-cell function, \nbodyweight, hypoglycaemia, \nand surrogate markers of \ncardiovascular risk (blood \npressure and heart rate). exenatide group had treatment \nfailure compared with 262 (54%) \nof 487 in the glimepiride group \n(risk diff erence 12\u00b74%, 95% CI \n6\u00b72\u201318\u00b76). hazard ratio 0.748 \n[0\u00b7623\u20130\u00b7899]; p=0\u00b7002. The \nupper onesided CI of the Cox \npropor tional hazard analysis \nwas 0\u00b7899, which was less than \nthe predefi ned non-inferiority \nvalue of 1.25. According to the \ntwo-sided 95% CI, exenatide \nwas more eff ective than \nglimepiride as add-on treatment \nfor patients with metformin \nfailure (95% CI 0\u00b7623\u20130\u00b7899; \np=0\u00b7002) nued : inter alia 49 had an adverse \nevent*,  4 patients died. In the \nglimepirid group 128 disconti-\nnued  inter alia 17 adverse event*, 2 \npatients died. *p=0\u00b7001 \nNo Blinding   \nThey declared non-inferiority of \nexenatide to glimepiride if the \n97\u00b75% CI for the hazard ratio (HR) ; \nif non-inferiority was shown, they  \ntested superiority with 95% CI. \nPower calculation: yes, but  they  \ncalculated sample size only on the \nbasis of the non-inferiority test of \nexenatide versus glimepiride, not for \nsuperiority \nRandomization : yes, described in \ndetail \nGroups similar  \nAEs described : yes \nCI  described : yes \nFlowchart : yes \nFunding Eli Lilly and Company; \nAmylin Pharmaceuticals. The spon-\nsor took part in study design, data \ncollection, data analysis, data inter-\npretation, and writing of the report. \nAll authors had full access to the \ndata and responsibility for the con-\ntent of the report. \nCOI : reported. First and last author G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          \n 55 \nQuelle/ \nStudientyp Population (verglichene) Interven-\ntionen/ \nggf. Dosierung/ \nggf. Follow-up Outcomes Ergebnisse Bemerkungen Eviden-\nzniveau \n(SIGN/ \nCEBM \nOxford) \nyears; evidence of \nrenal or liver disease \nor dysfunction; hae-\nmoglobinopathy or \nclinically signifi cant \nchronic anaemia; \nactive proliferative \nretinopathy or macular \noedema; or severe \ngastrointestinal di-\nsease. Excluded drugs \nwere those aff ecting \ngastrointestinal motili-\nty, chronic systemic \ngluco corticoids, \nprescription drugs to \npromote weight loss in \nthe past 3 months, \nand treatment for \nmore than 2 weeks in \nthe past 3 months with \ninsulin, thiazo lidine-\ndiones, \u03b1 -glucosidase \ninhibitors, sulphonylu-\nreas, or meglitinides. consultants  for Eli Lilly. Most of the \nCoauthors employees of Eli Lilly \nand Comp.  \nglimepiride dose used was fairly \nlow :  mean glimepiride dose was \n2\u202201 (SD 1\u202202) mg per day and \nMean exenatide dose was 17\u202235 \n(SD 4\u202207) \u03bcg per day \n \n G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          5 6  \n \n2 Evidenztabelle HbA1c-Senkung (und weitere Endpunkte)  \nZusammenstellung der Studienevidenz zum Kapitel Pharmakotherapie \nEvidenztabelle HbA1c-Senkung bei endpunktbezogenen Studien \u2013 Zusammenstellung Egidi/Abholz f\u00fcr DEGAM \u2013 Fassung 06/2012, Er-\ng\u00e4nzung \u00c4ZQ Feb. 2013 \n\u201cTitel\u201d (Jahr), \nAutor, Journal, \nStudientyp UKPDS 33 \n(1998), UKPDS \nGroup,  Lancet, \nRCT [16] UKPDS 34 \n(1998), UKPDS \nGroup, Lancet, \nRCT [17]  Kumamoto \n(1995), Ohkubo et \nal, Diab. Res. and \nClin. Prac., RCT \n[18] STENO-2 \n(2003), Gaede et \nal, NEJM, RCT [19]  PRO-ACTIVE \n(2005), Dormandy \net al, Lancet, RCT \n[20] ACCORD  \n(2008), Diabetes \nStudy group, \nNEJM, RCT [21]   ADVANCE \n(2008), ADVANCE \nCollaborative \nGroup, NEJM, RCT \n[22]  VADT \n(2008), Duckworth, \nNEJM, RCT [23] \n  \nPatientencharak-\nteristika Neu diagnostizier-\nter Diabetes, \n48-60 Jahre alt, \nMedian 54.  Wie UKPDS 33, \njedoch nur die \n\u00fcbergewichtigen \nund  adip\u00f6sen \nPatienten \n(BMI>25), mit \nzus\u00e4tzlicher Gabe \nvon Metformin  Insulin-behandelt, \ndurchschnittlich 48 \nJahre alt, duch-\nschnittlicher BMI \n21,5.  Mikroalbuminurie. \nDurchschnittliches \nAlter 55 Jahre, \ndurchschnittlicher \nBMI 30 kg/m2, \ndurchschnittlicher \nBlutdruck 148/86 \nmmHg Durchschnittlich 62 \nJahre alte Patien-\nten, 47 % nach \nInfarkt, 19 % nach \nInsult, 20 % mit \npAVK, BMI 31, RR \n144/83 mmHg Durchschnittliches \nAlter 62,2 Jahre, \ndurchschnittlicher \nBMI 32,2 kg/m2, \ndurchschnittlicher \nBlutdruck 136/75 \nmmHg, 35 % mit \nkardiovaskul\u00e4ren \nVorerkrankungen, \n65 % Wei\u00dfe, 14 % \nRaucher \u00dcber 55-j\u00e4hrige \nDiabetiker mit \nmakro- oder mikro-\nvaskul\u00e4ren Erkran-\nkungen oder mind. \n1 zus\u00e4tzlichen \nRisikofaktor \u2013 \nmeist aus dem \npazifischen Raum Im Schnitt 60,5-\nj\u00e4hrige m\u00e4nnliche \nVeteranen mit \nHbA1c >7,5 bzw- \n8,3 %.BMI 31,2, \nRR 132,76 mmHg, \n40 % makrovask. \n62 % mikrovask.- \nVorerkrankungem \nAusschluss-\nkriterien N\u00fcchtern-\nPlasmaglukose \n<60 oder \n>150mg % nach 3-\nmonatiger Di\u00e4t \nKetonurie, Niere-\nninsuffizienz \nKrea>1,75, makro-\nvaskul\u00e4re Erkran-\nkungen, Herzinsuf-\nfizienz, Retina-\nLaserung, maligne \nHypertonie, beru-Wie UKPDS 33, \naber BMI <25 Kreatinin >1,5 \nmg/dl, Alter \u00fcber \n70, normale Werte \nf\u00fcr Blutdruck und \nCholesterin, Keto-\nnurie, schwere \nDiabetes-\nKomplikationen \noder -Endpunkte \n Alter \u00fcber 65 und \nunter 40 Jahre, \nsekund\u00e4rer und \nTyp-1-Diabetes, \nAlkohol-\nMissbrauch, \nnichtdiabetische \nNephropathie, \nschwere Allgemei-\nnerkrankung Herzinsuffizienz, \nAlter < 35, >75, \nalleinige Insulinthe-\nrapie zuvor; kar-\ndiovaskul\u00e4re \nVorerkrankungen, \nBein-Ulcera, Le-\nberfunktions-\nSt\u00f6rung H\u00e4ufige Hypo-\nglyk\u00e4mien, Ableh-\nnung von Plasma-\nglukose-Kontrollen \nund Insulin-\nInjektionen, BMI \n>45 kg/m2 oder \nKreatinin >1,5 \nmg%. Kontraindikation \ngegen oder zwin-\ngende Indikation \nf\u00fcr eines der Stu-\ndienmedikamente. symptomatische \nStenokardien, \nHerzinsuffizienz, \nKreatinin \u00fcber 1,6 \nmg/dl, erwartete \nLebenserwartung \nunter 7 Jahre, BMI \n\u00fcber 40 kg G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          5 7  \n\u201cTitel\u201d (Jahr), \nAutor, Journal, \nStudientyp UKPDS 33 \n(1998), UKPDS \nGroup,  Lancet, \nRCT [16] UKPDS 34 \n(1998), UKPDS \nGroup, Lancet, \nRCT [17]  Kumamoto \n(1995), Ohkubo et \nal, Diab. Res. and \nClin. Prac., RCT \n[18] STENO-2 \n(2003), Gaede et \nal, NEJM, RCT [19]  PRO-ACTIVE \n(2005), Dormandy \net al, Lancet, RCT \n[20] ACCORD  \n(2008), Diabetes \nStudy group, \nNEJM, RCT [21]   ADVANCE \n(2008), ADVANCE \nCollaborative \nGroup, NEJM, RCT \n[22]  VADT \n(2008), Duckworth, \nNEJM, RCT [23] \n  \nfliche Gr\u00fcnde \ngegen Insulinbe-\nhandlung.Schwere \nKrankheit.  Kogni-\ntive St\u00f6rungen. \nUnkorrigierte \nendokrinologische \nSt\u00f6rungen \nPatientenzahl 3.867 753 (davon 342 \nmit Metformin) 110 160 5.238 10.251 11.140 1.791 \nStudienlaufzeit 10 Jahre 10,7 Jahre 6 Jahre 7,8 Jahre 2,9 Jahre Nach 3,5 Jahren \nabgebrochen \n(Blutzuckerarm) 4,3 Jahre 5,6 Jahre \nVerblindung Keine Keine Keine Keine Keine Keine Keine Keine \nFaktorielles De-\nsign Ja \u2013 zugleich \nUntersuchung RR-\nSenkung Wie UKPDS 33 Nein, aber zus\u00e4t-\nzliche Randomi-\nsierung in Prim\u00e4r- \nund Sekund\u00e4rpr\u00e4-\nventionsKohorte Nein Nein 3-fach-faktorielles \nDesign (Plasma-\nglukose-/RR- und \nLipid-Senkung) 2-fach-faktorielles \nDesign Nein \nEingesetzte \nSubstanz(en) Intensive Behand-\nlung mit  Chlorpro-\npamid, Gliben-\nclamid, Glipizid, \nInsulin versus \nkonventionelle \nBehandlung mit \nDi\u00e4t (bis max. \nN\u00fcchtern-BZ 15 \nmmol/l.)  Metformin vs-\n\u201ekonventionelle \nBehandlung\u201c  Insulin intensiviert \nvs konventionell \n(Mischinsulin)  intensive Ern\u00e4h-\nrungsberatung,  \n\u00bd Stunde Bewe-\ngungs-training 3-5 \nTage pro Woche, \nRaucher-\nEntw\u00f6hnung, 2x50 \nmg Captopril unab-\nh\u00e4ngig vom Blut-\ndruck, Vitamin C \nund E, ASS 150 Pioglitazon vs \nPlacebo als Zusatz \nzu laufender The-\nrapie mit Glibencla-\ncla-\nmid/Metformin/Insu\nlin Rosiglitazon 91 vs. \n58 %, Metformin \n95 vs 87 %, \nGlimepirid 78 vs \n68 %, Repaglinid \n50 vs 18 %, Alpha-\nGlukosidase-\nhemmer 23 vs 5 %, \nInkretin-Mimetika \n18 vs 5 %, Insulin \n77 vs 5 %. 10 vs \n1 % mit 4 und Intervention: Gli-\nclazid, andere SH-\nStoffe gestoppt. \nZus\u00e4tzlich Metfor-\nmin, Glitazon. \nInsulin, Acarbose \nzur Erreichung des \nHbA1c-Ziels \n(Intensive (Ziel \nHbA1c  6,5 %) \nversus Standard-Bei BMI >27 \nMetformin und \nRosiglitazon, bei \nBMI <27 Glimepirid \nund Rosiglitazon. \nInsulin dazu bei \nHbA1c >6 % in der \nInterventions- und \n>9 % in der Kon-\ntrollgruppe \n(Intensiv versus G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          5 8  \n\u201cTitel\u201d (Jahr), \nAutor, Journal, \nStudientyp UKPDS 33 \n(1998), UKPDS \nGroup,  Lancet, \nRCT [16] UKPDS 34 \n(1998), UKPDS \nGroup, Lancet, \nRCT [17]  Kumamoto \n(1995), Ohkubo et \nal, Diab. Res. and \nClin. Prac., RCT \n[18] STENO-2 \n(2003), Gaede et \nal, NEJM, RCT [19]  PRO-ACTIVE \n(2005), Dormandy \net al, Lancet, RCT \n[20] ACCORD  \n(2008), Diabetes \nStudy group, \nNEJM, RCT [21]   ADVANCE \n(2008), ADVANCE \nCollaborative \nGroup, NEJM, RCT \n[22]  VADT \n(2008), Duckworth, \nNEJM, RCT [23] \n  \nbei KHK, Metfor-\nmin bei \u00dcberge-\nwich-tigen, Glicla-\nzid bei Schlanken, \nTherapieintensi-\nvieung bei HbA1c \n7,0; Blutdruck-\nSenkung unter \n140/85 mmHg(ab \ndem Jahr 2000 \nunter 130/80, \nStatine bei Choles-\nterin > 5 mmol/l, \nzus\u00e4tzlich Fibrat \nbei Triglyceriden \n>4 mmol/l  \n(Intensive versus \nkonventionelle \nBehandlung mit \nunterschiedlichen \nBehandlungsziel-\nwerten )  mehr anti-\nglyk\u00e4mischen \nWirkstoffen \n(Intensive (Ziel \nHbA1c 6%) versus \nStandard-\nBehandlung (Ziel \nHbA1c  7-7.9%))  Behandlung (Ziel \n\u201edefined on the \nbasis of local \nguidelines\u201c)  Standard-\nBehandlung. Nach \nBZ-Kontrolle: \nMaximaldosis \nversus halbe \nDosis)  \nPrim\u00e4rer End-\npunkt Sammelendpunkt \naus allen denkba-\nren Diabetes-\nassoziierten \nEndpunkten. Nach \n10 Jahren Studien-\nlaufzeit Protokoll-\nwidrige Hinzuf\u00fc-\ngung des End-\npunktes Retina-\nKoagulation Wie UKPDS 33 Auftreten bzw. \nProgression von \nRetinopathie, \nNephropathie und \nNeuropathie  Sammelendpunkt: \nKardiovaskul\u00e4rer \nTod,Infarkt, By-\npass, PTCA, Insult, \nAmputation, Re-\nvakularisation \neiner Beinarterie  \nnach 8 Jahren  \nAuftreten einer \nNephropathie  nach Erstes Auftreten \njeweils eines der \ngenannten Erei-\ngnisse \n(kombinierter \nEndpunkt aus \nGesamtmortalit\u00e4t, \nHerzinfarkt, Schla-\nganfall, ACS, \nBypass-OP (kar-\ndial/ peripher), Herzinfarkt, Schla-\nganfall oder kar-\ndiovaskul\u00e4rer Tod  Herzinfarkt, \nSchlaganfall, \nNephropathie, \nRetinopathie , \nKardiovaskul\u00e4rer \nTod \n(kombinierter \nEndp. mikro- und \nmakrovask. Erei-\ngnisse,  getrennt \nmakrovas. und Zeit bis zum ersten \nkardiovaskul\u00e4ren \nEreignis (komb. \nEndp. aus Herzin-\nfarkt, Schlaganfall, \nkardiovask. Tod, \nHerzinsuff., By-\npass-OP (kardial/ \nperipher, zerebral), \nAmputation)  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          5 9  \n\u201cTitel\u201d (Jahr), \nAutor, Journal, \nStudientyp UKPDS 33 \n(1998), UKPDS \nGroup,  Lancet, \nRCT [16] UKPDS 34 \n(1998), UKPDS \nGroup, Lancet, \nRCT [17]  Kumamoto \n(1995), Ohkubo et \nal, Diab. Res. and \nClin. Prac., RCT \n[18] STENO-2 \n(2003), Gaede et \nal, NEJM, RCT [19]  PRO-ACTIVE \n(2005), Dormandy \net al, Lancet, RCT \n[20] ACCORD  \n(2008), Diabetes \nStudy group, \nNEJM, RCT [21]   ADVANCE \n(2008), ADVANCE \nCollaborative \nGroup, NEJM, RCT \n[22]  VADT \n(2008), Duckworth, \nNEJM, RCT [23] \n  \n4 Jahren  Amputation)   mikorvask. \nEreignisse) \nSekund\u00e4re End-\npunkte 21 klinische \nEndpunkte einzeln \nwie z. B. Herzin-\nfarkt; \n7 aggregierte \nEndpunkte  21 klinische \nEndpunkte einzeln \nwie z. B. Herzin-\nfarkt  \n7 aggregierte \nEndpunkte   Inzidenz von \nRetinopathie und \nNeuropathie Nicht pr\u00e4definiert!  Mortalit\u00e4t, Hypo-\nglyk\u00e4mien, Le-\nbensqualit\u00e4t Gesamt-\nSterblichkeit, \nHerzinsuffizienz, \nDemenz, Sehver-\nschlechterung, \nKrankenhausein-\nweisung Stenokardien, \nClaudicatio, Tod, \nTIA, mikrovask. \nKomplikstionen, \nHypoglyk\u00e4mien \nAusgewogene \nBegleitbe-\nhandlung ?? ?? ?? Es handelte sich \nbereits um eine \nkomplexe Interven-\ntion Ja Ja Nein \u2013 fast 3x so \nviele Studien-\nVisiten in der \nInterventions-\nGruppe, st\u00e4rkere \nRR-Senkung \n(136/74 vs \n138/74), ASS 64,1 \nvs. 61,1 % Ja \nHbA1c-Senkung  Senkung von 7,9 \nauf 7,0 %,  Senkung von 8,0 \nauf 7,4 % Senkung von 9,1 \nauf 7,1 % Interventions-\nGruppe \n8,4=>7,6 %, Kon-\ntrollgruppe \n8,8=>9,0 % Senkung von 7,9 \nauf 7,1 % Senkung von 8,1 \nauf 6,4 % (Kon-\ntrollgruppe 7,5 %) von 7,5 auf 6,5 % \nInt-Gruppe (Kon-\ntrollgruppe auf \n7,0 %) von 9,4 auf 6,4 % \nresp. auf 8,4 % \nARR prim\u00e4rer \nEndpunkt  3,2 %   13,5 %, p=0.002 Prim\u00e4rpr\u00e4v.-\nKohorte Retinopa-\nthie 11,5 %, \nNephropathie \n2,8 %  \nSek-Pr\u00e4v-Kohorte \nRetinopathie 12 %, \nNephropathie 4 % 20 % f\u00fcr kardio-\nvask. Ereignisse \n(p=0.007)  \nNephropathie \n18,75 %, \nRetinopathie \n16,25 %, \nNeuropathie Nicht errechenbar \n\u2013 keine signifikante \nEndpunkt-Senkung \n(HR 0.90; 95% CI \n0.80-1.02, p= \n0,095)  ARR 0.3 % (HR \n0.90; 95% CI 0.78-\n1.04, p=0.16)  1,1 % Nephropa-\nthie, HR 0.79: 95% \nCI 0.66-0.93, p= \n0.006 \nprim. Endp.:  \nkombin.: ARR \n1.9%, HR 0.90; \n95% CI 0.82-0.98, Keine  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          6 0  \n\u201cTitel\u201d (Jahr), \nAutor, Journal, \nStudientyp UKPDS 33 \n(1998), UKPDS \nGroup,  Lancet, \nRCT [16] UKPDS 34 \n(1998), UKPDS \nGroup, Lancet, \nRCT [17]  Kumamoto \n(1995), Ohkubo et \nal, Diab. Res. and \nClin. Prac., RCT \n[18] STENO-2 \n(2003), Gaede et \nal, NEJM, RCT [19]  PRO-ACTIVE \n(2005), Dormandy \net al, Lancet, RCT \n[20] ACCORD  \n(2008), Diabetes \nStudy group, \nNEJM, RCT [21]   ADVANCE \n(2008), ADVANCE \nCollaborative \nGroup, NEJM, RCT \n[22]  VADT \n(2008), Duckworth, \nNEJM, RCT [23] \n  \n23,75 %, \nErblindung 7,5 % p=0.01) \nmakrovask.: \nn.s.,  ARR 0.6%, \nHR 0.94; 95% CI \n0.84-1.06, p=0.32) \nmikrovask.: \nARR 1.5%, HR \n0.86; CI 95% 0.77-\n0.97, P=0.01)  \nNNT/Jahr \nprim\u00e4rer End-\npunkt  310  79 Prim\u00e4rpr\u00e4vention \nRetinopathie  52 \nNephropathie 214 \nSek-Pr\u00e4vention \nRetinopathie 50 \nNephropathie 2 Nephropathie 57 \nRetinopathie 110 \nErblindung 100 \nNeuropathie 110 \nKardiovask. Erei-\ngnisse 39 Nicht errechenbar \n\u2013 keine signifikante \nEndpunkt-Senkung n.s.  361 Nicht errechbar \u2013 \nkeine signifikante \nEndpunkt-Senkung \nARR makro-\nvaskul\u00e4re \nEreignisse  Nicht signifikant  Diabetes-\nMortalit\u00e4t 5,3 %, \np=0.001;  \nGesamt-Mortalit\u00e4t \n7,1 % p=0.01; \nHerzinfarkt 7,0 % \np=0.01  Nicht untersucht Nicht unterschie-\nden Nicht errechenbar \n\u2013 keine signifikante \nEndpunkt-Senkung Nicht zusam-\nmengefasst unter-\nsucht  Kein Unterschied Nicht errechbar \u2013 \nkeine signifikante \nEndpunkt-Senkung \nGesamtmorta-\nlit\u00e4t RR 0.94  \n(p=0.44; CI 0.80-\n1.10); ARR 1%  ARR Mortalit\u00e4t \n7,1 % p=0.01  n.u. n.u. Kein Unterschied , \nHR 0.96 (95% CI \n0,76-1.18), n.s.  HR 1.22 (95% CI \n1.01-1.46, p= 0.04) \nsek. Endp.) -> \ndaher Studienab-\nbruch nach 3,5 \nJahren in diesem \nStudienarm Kein Unterschied, \nHR 0.93; 95% KI \n0.83-1.06; p=0.28, \nn.s.) Kein Unterschied, \nHR 1.07, 95% KI \n0.81-1.42; p=0.62, \nn.s.) G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          6 1  \n\u201cTitel\u201d (Jahr), \nAutor, Journal, \nStudientyp UKPDS 33 \n(1998), UKPDS \nGroup,  Lancet, \nRCT [16] UKPDS 34 \n(1998), UKPDS \nGroup, Lancet, \nRCT [17]  Kumamoto \n(1995), Ohkubo et \nal, Diab. Res. and \nClin. Prac., RCT \n[18] STENO-2 \n(2003), Gaede et \nal, NEJM, RCT [19]  PRO-ACTIVE \n(2005), Dormandy \net al, Lancet, RCT \n[20] ACCORD  \n(2008), Diabetes \nStudy group, \nNEJM, RCT [21]   ADVANCE \n(2008), ADVANCE \nCollaborative \nGroup, NEJM, RCT \n[22]  VADT \n(2008), Duckworth, \nNEJM, RCT [23] \n  \nH\u00e4ufigkeit UAW  Schwere Hypo-\nglyk\u00e4mien (Hilfe \nDritter erforderlich) \npro Jahr 0,5 % \nunter Glibencla-\nmid, 2,2 % unter \nInsulin. Gewichts-\nzunahme Gliben-\nclamid 1,7 kg, \nInsulin 4 kg st\u00e4rker \nals in Ver-\ngleichsgruppe 6 % 6 Patienten in der \nInterventions- und \n4 in der Kontroll-\ngruppe mit milder \nHypoglyk\u00e4mie \u2013 \nbei keinem Hilfe \nDritter erforderlich Nicht unterschie-\nden Absolut 2 % mehr \nKrankenhaus-\nEinweisungen \nwegen kardialer \nDekompensatio-\nnen >10 kg Ge-\nwichtszunahme bei \n28 vs 14 %, \nschwere Hypo-\nglyk\u00e4mien (Hilfe \nDritter erforderlich) \nbei 10,5 vs 3,5 % \nStudie vorzeitig \nabgebrochen wg. \n\u00dcbersterblichkeit \n(nach 3.5 Jahren \n257 (5,01 %) vs. \n203 Tote (3,96 %) \nAbs. Risikoanstieg \n1,05 %, NNH= 95 Schwere Hypo-\nglyk\u00e4mien 2,7 vs \n1,5 % 24,1 vs 17,6 %. \nHypoglyk\u00e4mien \nwaren st\u00e4rkster \nPr\u00e4diktor f\u00fcr Ster-\nblichkeit. 1.333 vs. \n899 sympto-\nmatische Hypogly-\nk\u00e4mien \nNNH/Jahr UAW  NNH schwere \nHypoglyk\u00e4mie 71 \nbei Glibenclamid, \n56 bei Insulin  Schwere Hypo-\nglyk\u00e4mie 167 Nicht berechenbar Nicht berechenbar 144 f\u00fcr stat. Ein-\nweisung mit \nLungen\u00f6dem 95 f\u00fcr Tod \n50 f\u00fcr schwere \nHypoglyk\u00e4mien,  \n25 f\u00fcr Gewichtszu-\nnahme um >10 kg 358 f\u00fcr schwere \nHypoglyk\u00e4mien 75 \nRandomisierung + + (+), aber keine \nDetails beschrie-\nben + + (+), keine Details \nbeschrieben + + \nITT  + + + - + + + + \nPoweranalyse  (+) + - + + + (+), Anpassung im \nVerlauf durch \nStudienverl\u00e4nge-\nrung und Endpunk-\ntzusammenlegung + \nVergleichbarkeit  + + + +  + + + + G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          6 2  \n\u201cTitel\u201d (Jahr), \nAutor, Journal, \nStudientyp UKPDS 33 \n(1998), UKPDS \nGroup,  Lancet, \nRCT [16] UKPDS 34 \n(1998), UKPDS \nGroup, Lancet, \nRCT [17]  Kumamoto \n(1995), Ohkubo et \nal, Diab. Res. and \nClin. Prac., RCT \n[18] STENO-2 \n(2003), Gaede et \nal, NEJM, RCT [19]  PRO-ACTIVE \n(2005), Dormandy \net al, Lancet, RCT \n[20] ACCORD  \n(2008), Diabetes \nStudy group, \nNEJM, RCT [21]   ADVANCE \n(2008), ADVANCE \nCollaborative \nGroup, NEJM, RCT \n[22]  VADT \n(2008), Duckworth, \nNEJM, RCT [23] \n  \nder Gruppen (supplementary \nmaterial) \nad\u00e4quate Kon-\ntrollintervention + + + + + (+) - + \nKI Angabe + + - + + + + + \nCOI  n.a. n.a. - + + + + + \nSonstige Bemer-\nkungen  Wenig  Angaben \nzur genauen sta-\ntist. Auswertung in \ndieser Publikation \nzu finden; auch in \nder verwiesenenen \nPubl. zum Stu-\ndiendesign von \n1991 wenig kon-\nkrete Angaben \ndazu. Daher Po-\nwerberechung und \nad\u00e4quate Adjustie-\nrung  der Signifi-\nkanzniveaus  nur \neingeschr\u00e4nkt \nbeurteilbar. 7 \nverschiedene prim. \nEndpunkte und 21 \nsek. Endp, die \nfraglich alle a priori \nfestgelegt wurden. \nZur Begleittherapie \nim Verlauf kaum \nAngaben, nur Siehe UKPDS 34  Kleine Fallzahlen, \nSubgruppen der \neinzelnen Kohor-\nten jeweils ca. 25  \nPat.   Funded by Takeda \nand Lilliy  Major financial \nsponsor Servier, \nviele der  Autoren \nCOI durch Verbin-\ndung zu Servier \nund vielen weite-\nren PU 97% der Studien-\npopulation M\u00e4nner G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.\nNVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9   2 0 1 4          6 3  \n\u201cTitel\u201d (Jahr), \nAutor, Journal, \nStudientyp UKPDS 33 \n(1998), UKPDS \nGroup,  Lancet, \nRCT [16] UKPDS 34 \n(1998), UKPDS \nGroup, Lancet, \nRCT [17]  Kumamoto \n(1995), Ohkubo et \nal, Diab. Res. and \nClin. Prac., RCT \n[18] STENO-2 \n(2003), Gaede et \nal, NEJM, RCT [19]  PRO-ACTIVE \n(2005), Dormandy \net al, Lancet, RCT \n[20] ACCORD  \n(2008), Diabetes \nStudy group, \nNEJM, RCT [21]   ADVANCE \n(2008), ADVANCE \nCollaborative \nGroup, NEJM, RCT \n[22]  VADT \n(2008), Duckworth, \nNEJM, RCT [23] \n  \nBaselineangaben. \nEvidenzniveau \nnach SIGN 1(+) Siehe UKPDS 34 1(+) 1+ 1+ 1+ 1(+) 1+ \n \n G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  64 \n3 Abk\u00fcrzungsverzeichnis \nAbk\u00fcrzung  Erl\u00e4uterung (ggf. deutsche \u00dcbersetzung) \nAE  Adverse events \nCI oder KI  confidence interval oder Konfidenzintervall \nCoI conflicts of interest \nFEM fixed-effect model \nHR hazard ratio \nITT intention to treat \nMA metaanalysis \nn.r. not reported \nNNT number needed to treat \nns not significant \nOR odds ratio \nP Patients \nREM random-effect model \nRR risk ratio \nSR Systematic review \n \n  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  65 \n \n4 Literatur aus systematischen Review von Esposito et al. \n(2012) [7] \n1. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 St udy Investigators. The treat-to-target trial: randomized addition  of glargine or \nhuman NPH insulin to oral therapy of type 2 diabet ic patients. Diabetes Care. 2003;26(11):3080-3086. \n2. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Lispro Mixture-Glargine Study Group. Combined therapy with insuli n \nlispro Mix 75/25 plus metformin or  insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patie nts with \ntype 2 diabetes beginning insulin therapy. Clin Ther. 2004;26(12):2034-2044. \n3. Raskin P, Allen E, Hollander P, et al. Initiating insulin th erapy in type 2 diabetes: a comparison of biphasic and basal ins ulin analogs. \nDiabetes Care. 2005;28(2):260-265. \n4. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patien ts \nwith suboptimally controlled type 2 diabetes: a random ized trial. Ann Intern Med. 2005;143(8):559-569. \n5. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA , Yki-J\u00e4rvinen H. Comparison of basal insulin added to oral agen ts \nversus twice-daily premixed insulin as initial insulin t herapy for type 2 diabetes. Diabetes Care. 2005;28(2):254-259. \n6. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin th erapy \nalone results in better overall glycaemic control in patients with Type 2 diabetes. Diabetic Med. 2005;22(4):374-381. \n7. Davies M, Storms F, Shutler S, Bianchi-Biscay  M, Gomis R, for the Atlant us Study Group. Improvement of glycemic control in s ubjects \nwith poorly controlled type 2 diabetes. Compar ison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28(6 ):1282-\n1288. \n8. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 pl us metformin \nversus once-daily insulin glargine plus glimepiride . Exp Clin Endocrinol Diabetes. 2006;114(9):527-532. \n9. Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-na\u00efve patients \nwith type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab. 2006;8(4):448-55. \n10. Kazda C, H\u00fclstrunk H, Helsber g K, Langer F, Forst T, Hanefel d M. Prandial insulin substitution with insulin lispro or insul in lispro mid \nmixture vs. basal therapy with insulin glargine: a randomized c ontrolled trial in patients with type 2 diabetes beginning insul in therapy. J \nDiabetes Complications. 2006;20(3):145-152. \n11. Kennedy L, Herman WH, Strange P, Harris A; GOAL A1C Team. Impac t of active versus usual algorithmic titration of basal insu lin and \npoint-of-care versus laboratory measurement of HbA1c on glycemic  control in patients with type 2 diabetes: the Glycemic Optimiz ation \nwith Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29(1):1-8. \n12. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target t rial \ncomparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2  diabetes. \nDiabetes Care. 2006;29(6):1269-1274. \n13. Rosenstock J, Sugimoto D, Strange P, St ewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargin e or rosiglita-\nzone added to combination therapy of sulfonylurea plus metformin  in insulin-naive patients. Di abetes Care. 2006;29(3):554-559. \n14. Gerstein HC, Yale JF, Harri s SB, Issa M, Stewart JA, Dempsey E. A randomiz ed trial of adding insulin glargine vs. avoidance  of insulin in \npeople with Type 2 diabetes on either no oral glucose-lowering agent s or submaximal doses of metf ormin and/or sulphonylureas. T he \nCanadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabetic Med. \n2006;23(7):736-742. \n15. Standl E, Maxeiner S, Raptis S; HOE 901/4009 Study Group. Once-daily insulin glargine administration in the morning compared  to \nbedtime in combination with morning glimepiride in patients with  type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res. \n2006;38(3):172-177. \n16. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic , prandial, or basal insulin to oral therapy in type 2 diabetes . N Engl J Med. \n2007;357\n(17):1716-1730. \n17. Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insuli n analogue, \nboth plus metformin, in the achievement of target HbA1c and pr e- and postprandial blood glucose levels in patients with type 2 diabetes: \na multinational, 24-week, randomized, open-label, paralle l-group comparison. Clin Ther. 2007;29(11):2349-2364. \n18. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patient s with type 2 diabe-\ntes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover no ninferiority \ntrial. Clin Ther. 2007;29(11):2333-2348. \n19. Esposito K, Maiorino MI, Ci otola M, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens \nfor patients with suboptimal glycemic  control: a randomized trial. Ann Intern Med. 2008;149(8):531-539. \n20. Bretzel RG, Nuber U, Landgraf W, Owens DR,  Bradley C, Linn T. Once-daily basal in sulin glargine versus thrice-daily prandia l insulin \nlispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. \n2008;371(9618):1073-1084. G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  66 \n21. Rosenstock J, Davies M, Home PD, La rsen J, Koenen C, Schernthaner G. A randomis ed, 52-week, treat-to-target trial comparing  insulin \ndetemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabete s. Dia-\nbetologia. 2008;51(3):408-4016. \n22. Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 2 4-week \nresults: safety and efficacy of insulin lispro mix 75/25 versus  insulin glargine added to oral antihyperglycemic drugs in patie nts with type 2 \ndiabetes. Diabetes Care. 2009;32(6):1007-1013. \n23. Raz I, Wilson PW, Strojek K, et al. Effects of prandial ve rsus fasting glycemia on cardio vascular outcomes in type 2 diabet es: the \nHEART2D trial. Diabetes Care. 2009;32(3):381-386. \n24. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and su lfonylurea \ntherapy in type 2 diabetes mellitus (LEAD-5 met+SU): a random ised controlled trial. Diabeto logia. 2009;52(10):2046-2055. \n25. Blickl\u00e9 JF, Hancu N, Piletic M, et al. Insulin glargine provides greater im provements in glycaemic control vs. intensifying  lifestyle man-\nagement for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab. \n2009;11(4):379-386. \n26. Blonde L, Merilainen M, Karwe V, Rask in P; TITRATE Study Group. Patient-direct ed titration for achieving glycaemic goals us ing a once-\ndaily basal insulin analogue: an assessment of two different fast ing plasma glucose targets - the TITRATE study. Diabetes Obes Metab. \n2009;11(6):623-631. \n27. Rosenstock J, Eliaschewitz FG, Heilmann CR, Muchmore DB, Haye s RP, Belin RM. Comparison of prandial AIR inhaled insulin alo ne to \nintensified insulin glargine alone and to AIR insulin plus intens ified insulin glargine in patients with type 2 diabetes previo usly treated with \nonce-daily insulin glargine. Diabetes Technol Ther. 2009;11(Suppl 2):S63-73. \n28. Strojek K, Bebakar WM, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine i n patients with \ntype 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin. 2009;25(12):2887- 2894.  \n29. Fogelfeld L, Dharmalingam M, Robling K,  Jones C, Swanson D, Jacober S. A Randomiz ed, treat-to-target trial comparing insuli n lispro \nprotamine suspension and insulin detemir in insulin-na\u00efve pat ients with type 2 diabetes. Di abetic Med. 2010;27(1):181. \n30. Heise T, Mathieu C, Hey-Hadavi J, St rack T, Lawrence D. Glycemic control with preprandial versus basal insulin in patients with type 2 \ndiabetes mellitus poorly controlled by oral antidiabet es agents. Diabetes Technol  Ther. 2010;12(2):135-141. \n31. Kalra S, Plata-Que T, Kumar D, et al. Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin g largine in \nAsians with type 2 diabetes inadequately controlled by oral an ti-diabetic drugs. Diab Res Clin Pract. 2010;88(3):282-288. \n32. Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargin e once-daily \nwith insulin detemir twice-daily in patients with type 2 dia betes inadequately controlled on oral glucose-lowering drugs. Diabe tes Care. \n2010;33(6):1176-1178. \n33. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenat ide compared with insulin glargine titrated to target in patient s with type 2 \ndiabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234-2243. \n34. Strojek K, Shi C, Carey MA, Jacober SJ. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regi-\nmens: a randomized trial. Diabetes Obes Metab. 2010;12(10):916-922. \n35. Yki-J\u00e4rvinen H, Dressler A, Ziemen M,  and HOE 901/300s Study Group Less nocturnal hypoglycemia and better post-dinner gluco se \ncontrol with bedtime insulin glargine compared with bedtime NP H insulin during insulin combination therapy in type 2 diabetes. HOE \n901/3002 Study Group. Diabetes Care. 2000;23(8):1130-1136. \n36. Rosenstock J, Schwartz  SL, Clark CM, Jr, Park GD, Donley DW, Edwards MB. Basal Insulin Therapy in Type 2 Diabetes: 28-week \ncomparison of insulin glargine (HOE 901) and NPH insulin  Diabetes Care. 2001;24(4):631-636. \n37. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-y ears, randomised, multicentre trial comparing insulin glargine w ith NPH \ninsulin in combination with oral agents in patients wi th type 2 diabetes. Horm Metab Res. 2003;35(3):189-196. \n38. Fritsche A, Schwei tzer MA , H\u00e4ring HU: 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral prota-\nmine hagedorn insulin, or bedtime insulin glargine in patients with  type 2 diabetes. A randomized, controlled trial. Ann Intern  Med. \n2003;138(12):952-959. \n39. Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combinati on with \nglimepiride. Arch Med Res. 2006;37(4):495-501. \n40. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts  VL, Thorsteinsson B. Comparis on of once-daily insulin detemir  with \nNPH insulin added to a regimen of oral antidiabetic drugs in  poorly controlled type 2 diabetes. Clin Ther. 2006;28(10):1569-158 1. \n41. Yki-J\u00e4rvinen H, Kauppinen-M\u00e4kelin R, Tiikkainen M, et al. Insu lin glargine or NPH combined with metformin in type 2 diabete s: the \nLANMET study. Diabetologia. 2006;49(3):442-451. \n42. Yki-J\u00e4rvinen H, Juurinen L, Alvarsson M, et al. Initiate  insulin by aggressive titration and education (INITIATE): a random ized study to \ncompare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007;3 0(6):1364-\n1369. \n43. Pan CY, Sinnassamy P, Chung KD, Kim KW: LEAD Study Investigat ors Group. Insulin glargine versus NPH insulin therapy in Asia n type \n2 diabetes patients. Diabetes Res Clin Pract. 2007;76(1):111-118. \n44. Bunck MC, Diamant M, Corn\u00e9r A, et al. One-year treatment with exenatide improves \u03b2-cell function, compared with insulin glargine, in \nmetformin-treated type 2 diabetic patients: A randomized, controlled trial. Diabetes Care. 2009 32(5):762-768. \n45. Malone JK, Beattie SD, Campaigne BN, Johnson PA, Howard AS, Milicevic Z. Therapy after si ngle oral agent failure: adding a second \noral agent or an insulin mixture? Diabetes Res Clin Pract. 2003;62(3):187-195. G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  67 \n46. Ushakova O, Sokolovskaya V, Morozova A, et al. Comparison of biphasic insulin aspart 30 given three times daily or twice da ily in com-\nbination with metformin versus oral antidiabetic drugs alone in  patients with poorly controlled type 2 diabetes: a 16-week, ran domized, \nopen-label, parallel-group trial conducted in russia. Clin Ther. 2007;29(11):2374-2384. \n47. Nauck MA, Duran S, Kim D, al. A comparison of twice-daily  exenatide and biphasic insulin aspart in patients with type 2 dia betes who \nwere suboptimally controlled with sulf onylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259-267. \n48. Hirao K, Arai K, Yamauchi M, Takagi H, Kobayashi M; Japan Diabetes Clinical Data Manag ement Study Group. Six-month multicen tric, \nopen-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple  daily injections of insuli n aspart in Japa-\nnese type 2 diabetic patients (JDDM 11). Di abetes Res Clin Pract. 2008;79(1):171-176. \n49. Rosenstock J, Ahmann AJ, Colo n G, Scism-Bacon J, Jiang H, Martin S. Advanc ing insulin therapy in type 2 diabetes previously  treated \nwith glargine plus oral agents: prandial premixed (insulin lispr o protamine suspension/lispro) ve rsus basal/bolus (glargine/lis pro) therapy. \nDiabetes Care. 2008;31(1):20-52. \n50. Yang W, Ji Q, Zhu D, et al. Biphasic insulin aspart 30 thr ee times daily is more effective than a twice-daily regimen, with out increasing \nhypoglycemia, in Chinese subjects with type 2 diabetes inad equately controlled on oral antidiabetes drugs. Diabetes Care. \n2008;31(5):852-856. \n51. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B. Comparison of insulin analogue regimens in people with type 2 diabetes \nmellitus in the PREFER Study: a randomized controll ed trial. Diabetes Obes Metab. 2009;11(1):45-52. \n52. Raskin P, Matfin G, Schwartz SL, et al. Addition of bip hasic insulin aspart 30 to optim ized metformin and pioglitazone trea tment of type 2 \ndiabetes mellitus: The ACTION Study (Achieving Control Through Insulin  plus Oral ageNts). Diabetes  Obes Metab. 2009;11(1):27-32 . \n53. Cucinotta D, Smirnova O, Christiansen JS, et al. Three diffe rent premixed combinations of biphasic insulin aspart - compari son of the \nefficacy and safety in a randomized controlle d clinical trial in subjects with type 2 diabetes. Diabetes Obes Metab. 2009;11(7) :700-708. \n54. Oyer DS, Shepherd MD, Coulter FC, et al . A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATE plus \ntrial). Am J Med. 2009;122(11):1043-1049. \n55. Bergenstal R, Lewin A, Bailey T, Chang D,  Gylvin T, Roberts V. Efficacy and safety  of biphasic insulin aspart 70/30 versus exenatide in \nsubjects with type 2 diabetes failing to ac hieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin. 2009;25 (1):65-\n75. \n56. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insu lin plus basal insulin glargine versus twice daily biaspart i nsulin for type 2 \ndiabetes: a multicentre randomised tr ial. Lancet. 2010;375(9733):2244-2253 \n57. Jain SM, Mao X, Escalante-Pulido M, Vo rokhobina N, Lopez I, Ilag LL. Prandial-basal insulin regimens plus oral antihypergly caemic \nagents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Meta b. \n2010;12(11):967-975. \n58. Gallwitz B, B\u00f6hmer M, Segiet T, et al. Exenatide twice dail y versus premixed insulin aspart 70/30 in metformin-treated pati ents with type \n2 diabetes: a randomized 26-week study on glycemic cont rol and hypoglycemia. Diabetes Care. 2011;34(3):604-606.  \n59. Roach P, Yue L, Arora V. Improved post prandial glycemic control during treatment with Humalog Mix25, a novel protamine-base d insulin \nlispro formulation. Humalog Mix25 Stud y Group. Diabetes Care. 1999;22(8):1258-1261. \n60. Herz M, Sun B, Milicevic Z, et al. Comparative efficacy of preprandial or postprandial humalog@ Mix75/25 versus glyburide in patients 60 \nto 80 years of age with type 2 diabete s mellitus. Clin Ther. 2002;24(1):73-86. \n61. Roach P, Arora V, Campaigne BN, Mattoo V, Rangwala S: The India Mi x25/Mix50 Study Group. Humal og Mix50TM before carbohydrat e-\nrich\n meals in type 2 diabetes mellitus.  Diabetes Obes Metab. 2003;5(5):311\u2013316. \n62. Tigoviste CI, Strachinariu R, Farcasiu  E, Milicevic Z, Teodirescu G. Humalog Mix 25 in patients with type 2 diabetes which do not achieve \nacceptable glycemic control with oral a gents: results from a phase III, randomized, parallel study. Rom J Intern Med. 2003;41(2 ):152-162. \n63. Christiansen JS, Vaz JA, Metelko Z, Bogoev M, Dedov I. Twic e daily biphasic insulin aspart improves postprandial glycaemic control \nmore effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes Diabetes Obes M etab. \n2003;5(6):446\u2013454. \n64. Kilo C, Mezitisb N, Jainc R, Merseyd J, McGille J, Raskin  P. Starting patients with type 2 diabetes on insulin therapy usin g once-daily \ninjections of biphasic insulin aspart 70/30, biphasic human insulin  70/30, or NPH insulin in combination with metformin. J Diab etes Com-\nplications. 2003;17(6):307-313. \n65. Schernthaner G, Kopp H-P, Ristic S, Muzyka B, Peter L, Mi tteregger G. Metabolic control in patients with type 2 diabetes us ing humalog \nMix50 injected three times daily: crossover comparison with  human insulin 30/70. Horm Metab Res. 2004;36(3):188-193. \n66. Niskanen L, Jensen LE, R\u00e5stam J, Nygaard-Pedersen L, Er ichsen K, Vora JP. Randomized, multinational, open-label, 2-\nperiod,crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with  type 2 dia-\nbetes mellitus. Clin Ther. 2004;26(4):531\u2013540. \n67. Boehm BO, Vazb JA, Brondstedb L, Home PD. Long-term efficacy  and safety of biphasic insulin aspart in patients with type 2 diabetes. \nEur J Inter Med. 2004;15(8):496\u2013502. \n68. Abrahamian H, Ludvik B, Sc hernthaner G, et al. Improvement of glucose to lerance in type 2 diabetic patients: traditional vs  modern \ninsulin regimens (results from the Austrian Bi aspart Study). Horm Metab Res. 2005;37(11):684-9. \n69. Raz I, Stranks S, Filipczak R, et al . Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly \ncontrolled on glibenclamide (glyburide) monotherapy or combinat ion therapy: an 18-week, randomized, open-label study. Clin Ther . \n2005;27(9):1432-1443. G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  68 \n70. Ligthelm R, Mouritzen U, Lynggaard H, et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus regimen with four \ndaily injections. A randomised open-label parallel group four months  comparison in patients with type 2 diabetes. Exp Clin Endo crinol Di-\nabetes. 2006;114(9):511\u2013519. \n71. Kvapil M, Swatko A, Hilberg C, Shesta kova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. \nDiabetes Obes Metab. 2006;8(1):39\u201348. \n72. Milicevic Z, Hancu N, Car N, Ivanyi  T,  Schwarzenhofer M, Jermendy G. Effect of tw o starting insulin regimens in patients w ith type II \ndiabetes not controlled on a combination of oral antihyperglyc emic medications. Exp Clin Endocrinol Diabetes. 2009; 117(15):223 \u2013229. \n73. Lund SS, Tarnow L, Frandsen M, et al. Combining insulin with  metformin or an insulin secretagogue in non-obese patients wit h type 2  \ndiabetes: 12 month, randomised, double blind trial. BMJ. 2009;339:b4324 \n74. Bastyr EJ 3rd, Stuart CA, Brodows RG, et al. Therapy focus ed on lowering postprandial glucose, not fasting glucose, may be superior for \nlowering HbA1c. IOEZ Study Group. Diabetes Care. 2000;23(9):1236-1241. \n75. Kawamori R, Iwamoto Y, Kadowaki T, et al. Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 d iabetes melli-\ntus. Diabetes Obes Metab. 2009;11(9):900-909. \n76. Gross JL, Nakano M, Colon-Vega G, et al. Initiation of prandi al insulin therapy with AIR inhaled insulin or insulin lispro in patients with \ntype 2 diabetes: A randomized noninferiority trial.  Diabetes Technol Ther. 2009;11(Suppl 2):S27-34. \n77. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime trea tment with insulin analog improves postprandial hyperglycemia a nd hypo-\nglycemia in patients with non-insulin-dependent diabet es mellitus. Arch Intern Med. 1997;157(11):1249-1255. \n78. Ross SA, Zinman B, Campos RV, Strack T: Canadian Lispro Study Group. A comparativ e study of insulin lispro and human regula r \ninsulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agen ts. Clin Invest Med. 2001;24(6 ):292-298. \n79. Forst T, Eriksson JW, Strotmann HJ, et al. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in e arly type 2 \ndiabetes. Exp Clin Endocrinol Diabetes. 2003;111(2):97-103. \n80. Bretzel RG,  Arnolds S, Medding J, Linn T. A direct effica cy and safety comparison of insulin aspart, uman soluble insulin,  and human \npremix insulin (70/30) in patients with ty pe 2 diabetes.  Diabetes Care. 2004; 27(5):1023-1027. \n81. Hollander P, Cooper J, Bregnh\u00f8j J, Pedersen CB. A 52-week , multinational, open-label, parallel-group, noninferiority, treat -to-target trial \ncomparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 d iabetes. Clin \nTher. 2008;30(11):1976-1987. \n82. Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate \ncounting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31(7):1305-1310. \n83. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA. Introducing a simplified approach to insulin therapy in type 2 diabetes: a  compari-\nson of two single-dose regimens of insulin glulisine plus insu lin glargine and oral antidiabetic drugs. Diabetes Obes Metab. \n2008;10(12):1178-1185. \n84. Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L. Randomized co mparison of pramlintide or mealtime insulin  added \nto basal insulin treatment for patients with type 2 diabetes. Diabetes Care. 2009;32(9):1577-1582. \n85. Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insu lin detemir and insulin glargine using a basal-bolus regimen in a random-\nized, controlled clinical study in patients with ty pe 2 diabetes. Diabetes Metab Res Rev. 2009;25(6):542-548. \n86. Fritsche A, Larbig M, Owens  D, H\u00e4ring H-U; on behalf of the GINGER study group. Comparison between a basal-bolus and a prem ixed \ninsulin regimen in individuals with type 2 diabetes- Results of  the GINGER study. Diabetes Obes Metab. 2010;12(2):115-123. \n87. Ra\u0161lov\u00e1 K, Bogoev M, Raz I, Leth G, Ga ll M-A, Hancu N. Insulin detemir and insu lin aspart: a promising basal-bolus regimen for type 2 \ndiabetes. Diabetes Res Clin Pract. 2004;66(2):193\u2013201. \n88. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W. Lower within-subject va riability of fasting blood glucose and reduced w eight gain \nwith insulin detemir compared to NPH insulin in patients w ith type 2 diabetes Diabetes Obes Metab. 2005;7(1):56\u201364. \n89. Yokoyama H, Tada J, Kamikawa F, Kanno S, Yokota Y, Kuramits u M. Effect of conversion from bedtime NPH insulin to morning in sulin \nglargine in type 2 diabetic patients on basal-prandial in sulin therapy. Diabetes Res Clin Pract. 2006;73(1):35-40. \n90. Buse JB, Henry RR, Han J, Kim DD, Finem an MS, Baron AD.  Effects of exenatide (Ex endin-4) on glycemic control over 30 weeks  in \nsulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628\u20132635. \n91. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of e xenatide (Exendin-4) on glycemic control over 30 weeks in patients  with type 2 \ndiabetes treated with metformin and a sulf onylurea. Diabetes Care. 2005;28(5):1083\u20131091. \n92. DeFronzo R, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD.  Effects of exenatide (Exendin-4) on glycemic control and weigh t over \n30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092\u20131100. \n93. Zinman B, Hoogwerf BJ, Duran Garcia SD , et al. The effect of adding exenatide to  a thiazolidinedione in suboptimally contro lled type 2 \ndiabetes. A randomized trial. Ann Intern Med. 2007;146(7):477-485. \n94. Forti A, Garcia EG, Yu MB, Jimenez MC, Brodows RG, Oliveira  JH. Efficacy and safety of ex enatide administered before the tw o largest \ndaily meals of Latin American patients with type 2 diabetes. Curr Med Res Opin. 2008;24(9):2437-2447. \n95. Moretto TJ, Milton DR, Ridge TD, et al . Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic dr ug-naive \npatients with type 2 diabetes: A randomized, double-blind, plac ebo-controlled, parallel-group study. Clinical Therapeutics. \n2008;30(8):1448-1460. \n96. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly  versus twice daily for the treatment of type 2 diabetes: a rand omised, open-\nlabel, non-inferiority study. Lancet. 2008;372(9645):1240-1250.  G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  69 \n97. Gao Y, Yoon KH, Chuang L-M, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inade quately \ncontrolled with metformin or metformin and a sul phonylurea. Diab Res Clin Pr. 2009;83(1):69-76. \n98. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day  for type 2 diabetes: a 26-week r andomised, \nparallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47. \n99. Derosa G, Maffioli P, Salvadeo SA, et  al. Exenatide versus glibenc lamide in patients with diabet es.  Diabetes Technol Thera p. \n2010;12(3):233-40. \n100. Apovian CM, Bergenstal RM, Cuddihy RM, et  al. Effects of exenatide combined with lif estyle modification in patients with t ype 2 diabetes. \nAm J Med. 2010;123(5):468.e9-468.e17. \n101. Liutkus J, Rosas Guzman JR, Norwood P, et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinedio nes alone or in \ncombination with metformin. Diabetes Obes Metab. 2010;12(12):1058-1065. \n102. Blevins T, Pullman J, Malloy J, et al.  DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Con trol \nCompared with Exenatide Twice Daily in Patients with Ty pe 2 Diabetes. J Clin Endocrinol Metab. 2011 Feb 9. \n103. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 Analog, given as monot herapy signifi-\ncantly improves glycemic control and lowers body weight wit hout risk of hypoglycemia in patients with type 2 diabetes. Diabetes  Care. \n2007;30(6):1608-1610. \n104. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monothe rapy for type 2diabetes (LEAD-3 Mono): a randomi sed, 52-\nweek, phase III, double-blind, parallel-tr eatment trial. Lancet. 2009;73(9662):473-478. \n105. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglut ide, glimepiride, and placebo, all in combi nation with \nmetformin, in type 2 diabetes. Diabetes Care. 2009;32(1):84-90. \n106. Zinman B, Gerich J, Buse JB, et al . Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combina tion with \nmetformin and thiazolidinedione in patients with type 2 di abetes (LEAD-4 Met_TZD). Diabetes Care. 2009;32(7):1224-2330. \n107. Marre M, Shaw J, Br\u00e4ndle M, et al . Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces \ngreater improvements in glycaemic and we ight control compared with adding rosiglitaz one or placebo in subjects with Type 2 diab etes \n(LEAD-1 SU). Diabetic Med. 2009;26(3):268-278.  \n108. Pratley RE, Nauck M, Bailey T, et al . Liraglutide versus sitagliptin for patie nts with type 2 diabetes who did not have ad equate glycaemic \ncontrol with metformin: a 26-week, randomised, paralle l-group, open-label trial. Lanc et. 2010;375(9737):1447-1456. \n109. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazo ne as an \nadjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomis ed trial. Lancet. 2010;376(9739):431-439. \n110. Ristic S, Byiers S, Foley, Holmes D. Improved glycaemic control with dipeptidy l peptidase-4 inhibition in patients with ty pe 2 diabetes: \nvildagliptin (LAF237) dose response. Di abetes Obes  Metab. 2005;7(6):692-698. \n111. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Effica cy and tolerability of vildagliptin monotherapy in drug-na \u0131\u00a8ve patients with type 2 \ndiabetes. Diabetes Res Clin Pract. 2007;76(1):132-138. \n112. Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1 c over 1 \nyear in drug-na\u00efve patients with Type 2 diabetes. Diabetic Med. 2007;24(9):955-961. \n113. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-na\u00efve patients with type 2 diabetes: a 24-Week, double-bli nd, random-\nized, placebo-controlled, multiple-dose st udy. Horm Metab Res. 2007;39(3):218-223. \n114. Rosenstock J,  Kim SW,  Baron MA, et al. Efficacy and tole rability of initial combination therapy with vildagliptin and pi oglitazone com-\npared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab.  2007;9(2):175-185. \n115. Gomis R, Espadero M-R, Jones R, Woerle H-J, Dugi KA. Efficacy and safety  of initial combination therapy with linagliptin a nd pioglita-\nzone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study. Diabetes O bes \nMetab. 2011 Jul;13:653-61. \n116. Yoon KH, Shocley GR, Teng R, Golm GT , Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H. \nEffect of initial combination therapy wi th sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic contro l and measures \nof beta-cell function in patients with type 2 diabetes. Intern J Clin Pr. 2011; 65:154-164. \n117. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in \npatients with type 2 diabetes failing thiazolidinedione monotherapy:  a randomized, placebo-contro lled study. Diabetes Obes Meta b. \n2007;9(2):166-174. \n118. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A.  Comparison of vildagliptin and rosiglitazone monotherapy in patie nts with \nType 2 diabetes. Diabetes Care. 2007;30(2):217-223. \n119. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patie nts with type 2 \ndiabetes inadequately controlled with metfo rmin. Diabetes Care. 2007;30(4):890-895. \n120. Garber AJ, Foley JE, Banerji MA, et al . Effects of vildagliptin on glucose cont rol in patients with type 2 diabetes inadequately controlled \nwith a sulphonylurea. Diabetes Obes Metab. 2008;10(11):1047-1056. \n121. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin : a 24-week, \nrandomized, double-blind study. Diabetes  Obes Metab. 2008;10(1):82-90. \n122. Pan C, Yang W, Barona JP, et al. Comparison of vildaglip tin and acarbose monotherapy in patients with Type 2 diabetes: a 2 4-week, \ndouble-blind, randomized trial. Diabetic Med. 2008;25(4):435-441. \n123. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week e fficacy and safety of vildagliptin vs. glimepiride in patients w ith type 2 diabetes \nmellitus inadequately controlled on metformin monot herapy. Diabetes Obes Metab. 2009;11(2):157-166. G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  70 \n124. Goodman M, Thurston H, Penman J. Effi cacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately c ontrolled with \nmetformin monotherapy. Horm Me tab Res. 2009; 41(5):368-373. \n125. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metform in combination therapy provides superior glycaemic control to individual \nmonotherapy in treatment-naive patients with type 2 diabet es mellitus. Diabetes Obes Metab. 2009;11(5):506-515. \n126. Schweizer A, Dejager S, Bosi E. Comparison of vildaglip tin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-\nweek, double-blind, randomized trial. Diabetes Obes Metab. 2009;11(8):804-812 \n127. Filozof C, Gautier JF.A comparison of efficacy and safety of vildagliptin and glic lazide in combination with metformin in patients with Type \n2 diabetes inadequately controlled with metformin alone: a 52- week, randomized study. Diabetic Med. 2010;27(3):318-26. \n128. Derosa G, Maffioli P, Ferrari I, et al. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride  in poorly controlled \ntype 2 diabetic patients. Horm Metab Res. 2010;42(9):663-669. \n129. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy  and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin  added to ongo-\ning metformin therapy in patients with type 2 diabetes inadequatel y controlled with metformin alone. Diabetes Care. 2006;29(12) :2638-\n2643. \n130. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and sa fety of the dipeptidyl peptidase-4 inhibito r sitagliptin as \nmonotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2564-2571. \n131. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing \npioglitazone therapy in patients with type 2 diabetes: a 24-week , multicenter, randomized, double-blind, placebo-controlled, pa rallel-group \nstudy. Clin Ther. 2006;28(10):1556-1568. \n132. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C,  Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibito r sitagliptin \nas monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637. \n133. Hermansen K, Kipnes M,  Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in \npatients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes O bes \nMetab. 2007;9(5):733-745. \n134. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipep-\ntidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979 -1987. \n135. Hanefeld M, Herman GA, Wu M, Mickel C, Sanchez M, Stein PP. Once-daily si tagliptin, a dipeptidyl peptidase-4 inhibitor, fo r the treat-\nment of patients with type 2 diabetes.  Curr Med Res Opin. 2007;23(6):1329-1339. \n136. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Effi cacy and safety of the dipeptidyl peptidase-4 inhibitor, sitag liptin, compared \nwith the sulfonylurea, glipizide, in patients with type 2 di abetes inadequately controlled on metformin alone: a randomized, do uble-blind, \nnon-inferiority trial. Diabetes Obes Metab. 2007;9(2):194-205. \n137. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerab ility of the dipeptidyl peptidase-4 inhibitor sitagliptin as monoth erapy over 12 \nweeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171-80. \n138. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety  of sitagliptin when added to ongo ing metformin therapy in patie nts with type \n2 diabetes. Diabetes Obes Metab. 2008;10(10):959-969. \n139. Raz I, Chen Y, Wu M, et al. Efficacy and safety of si tagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr \nMed Res Opin. 2008;24(2):537-550. \n140. Nonaka K, Kakikawa T, Sato A, et al . Efficacy and safety of sit agliptin monotherapy in Japanese patients with type 2 diabe tes. Diabetes \nRes Clin Pract. 2008;79(2):291-298. \n141. Mohan V, Yang W, Son HY, et al. Efficacy  and safety of sitagliptin in the treatment  of patients with type 2 diabetes in China, India, and \nKorea. Diabe\ntes Res Clin Pract. 2009;83(1):106-116. \n142. Derosa G, Maffioli P, Salv adeo SA, et al. Effects of sitagliptin or metfo rmin added to pioglitazone monotherapy in poorly controlled type 2 \ndiabetes mellitus patients. Metabolism. 2010;59(6):887-895. \n143. Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglit azone, or sitagliptin on glycemi c control and \nlipid profile in patients with type 2 diabetes mellitus inade quately controlled by metformin monotherapy. Endocr Pract. 2010;16 (1):53-63. \n144. Seck T, Nauck M, Sheng D, et al. Sitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizi de in patients with \ntype 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562-576. \n145. Aschner P, Katzeff HL, Guo H, et al. Sitagliptin Study 049 Group.Efficacy and safety of mono therapy of sitagliptin compare d with metfor-\nmin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(3):252-261. \n146. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of  treatment with sitagliptin or glimepiride in patients with t ype 2 diabetes \ninadequately controlled on metformi n monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. \n2011;13(2):160-168. \n147. Scheen AJ, Charpentier G, Ostgren CJ, Hellq vist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with  metformin \ncompared with sitagliptin in combination with metformin in adult patients with type 2 diabetes me llitus. Diabetes Metab Res Rev . \n2010;26(7):540-549.  \n148. Rosenstock J, Sankoh S, List JF. Gluc ose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-nai ve patients with \ntype 2 diabetes. Diabetes Obes Metab. 2008;10(5):376-386. \n149. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patient s with \ninadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649-1655. G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  71 \n150. Jadzinsky M, Pf\u00fctzner A, Paz-Pacheco E,  Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy \nimproves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Di abetes \nObes Metab. 2009;11(6):611-622. \n151. Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a th iazolidinedione improves glycemic control in patients with ty pe 2 diabetes \nand inadequate control on thiazolidinedione alone.  J Clin Endocrinol Metab. 2009;94(12):4810-4819. \n152. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-na\u00efve pa tients with type \n2 diabetes. Curr Med Res Opin. 2009; 25(10):2401-4211. \n153. Chacra AR, Tan GH, Apanovitch A, Ravi chandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonilurea i mproves \nglucaemic control compared with uptritation of sulphonylurea in  patients with type 2 diabetes: a randomized controlled trial. I ntern J Clin \nPract. 2009;63(9):1395-1406. \n154. G\u00f6ke B, Gallwitz B, Eriksson J, Hellqvi st A, Gause-Nilsson I. Saxagliptin is non- inferior to glipizide in patients with ty pe 2 diabetes melli-\ntus inadequately controlled on metformin alone: a 52-week randomis ed controlled trial. Int J Clin Pract. 2010;64(12);1619-1631.    \n155. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl  peptidase-4 inhibitor alogliptin in patie nts with type 2 \ndiabetes and inadequate glycemic control: a randomized, double-blin d, placebo-controlled study. Diabetes Care. 2008;31(12):2315-217. \n156. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Effica cy and safety of adding the dipeptidyl peptidase-4 inhibitor alogl iptin to met-\nformin therapy in patients with type 2 diabetes inadequately cont rolled with metformin monotherapy: a multicentre, randomised, double-\nblind, placebo-controlled study. Int J Clin Pract. 2009;63(1):46-55. \n157. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Effica cy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with \ntype 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Me tab. 2009;11(2):167-76. \n158. Pratley RE, Reusch JE, Fleck PR, Wils on CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor aloglipti n added to \npioglitazone in patients with type 2 diabetes: a randomized , double-blind, placebo-controlled study. Curr Med Res Opin. \n2009;25(10):2361-2371. \n159. Rosenstock J, In zucchi SE, Seufert J, Fleck PR, Wilson GA, Mekki Q. Initial combination therapy with alogliptin and piogli tazone in drug-\nna\u00efve patients with type 2 diabetes. Diabetes Care. 2010;33(11):2406-2408.  \n160. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ , Dugi KA. Effect of linagliptin monotherapy on glycaemic contro l and \nmarkers of \u03b2-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. \n2011;13(3):258-267. \n161. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX , Krol A. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-\ntreated NIDDM patients. Diabetes Care. 1994;17(1):20-29. \n162. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. European study on dose-response relationship of acar bose as \na first-line drug in non-insulin dependent diabetes mellitus: effi cacy and safety of low and high doses. Acta Diabetol. 1998;35 (1):34-40. \n163. Johnston PS, Lebovitz HE, Coniff RF, Si monson DC, Raskin P, Munera CL. Advantages of alpha-gl ucosidase inhibition as monot herapy \nin elderly type 2 diabetic patients. J Clin Endocrinol Metab. 1998;83(5):1515-1522. \n164. Mitrakou A, Tountas N, Raptis AE, Ba uer RJ, Schulz H, Raptis SA. Long-term ef fectiveness of a new alpha-glucosidase inhibi tor (BAY \nm1099-Miglitol) in insulin-treated type 2 diabe tes mellitus. Diabetic Med. 1998;15(8): 657-660. \n165. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in me tformin-treated patients with type 2 diabete s. Diabetes \nCare. 1998;21(12):2050-2055. \n166. Halimi S, Le Berre MA, Grange\u00b4 V. Efficacy and safety of acar bose add-on therapy in the treatment of overweight patients w ith Type 2 \ndiabete\ns inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2000; 50(1) :49\u201356. \n167. van Gaal L, Maislos M, Schernthaner G, Ry bka J, Segal P. Miglitol combined with metformin improves glycemic control in typ e 2 diabe-\ntes. Diabetes Obes Metab. 2001;3(5):326-331. \n168. Phillips P, Karrasch J, Scott R, Wilson D, Moses R. Acarbose improves  glycemic control in overweight type 2 diabetic patie nts insuffi-\nciently treated with metformin. Diabetes Care. 2003;26(2):269\u2013273. \n169. Chan JC, Chan KW, Ho LL, Fuh MM, Horn LC, Sheaves R. An Asian multicentre clinic  trial to assess the efficacy and tolerabi lity of \nacarbose compared with placebo in type 2 diabetic patients previously treated with diet. Diabetes Care. 1998;21(7):1058-1061. \n170. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improve  glycemic \ncontrol in the treatment of patients wi th type 2 diabetes: a 6-month randomized plac ebo-controlled dose-response study. The Pio glita-\nzone 001 Study Group. Diabetes Care. 2000; 23(11):1605\u20131611. \n171. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metf ormin and rosiglitazone combination therapy in patients wi th type 2 \ndiabetes mellitus. JAMA. 2000;283(13):1695-1702. \n172. Kipnes MS, Krosnick A, Rendel MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfo nylurea \ntherapy improves glycemic cont rol in patients with type 2 diabetes mellitus: a randomized, placebo-cont rolled study. Am J Med. \n2001;111(1):10-17. \n173. Lebovitz HE, Dole JF, Patwardhan R, Rappapor t EB, Freed MI. Rosiglitazone Clinical Trials Study Group. Rosiglitazone monot herapy is \neffective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001; 86(1): 280\u2013288. \n174. Phillips LS, Grunberger G, Miller E, et al. Rosiglitazone Clin ical Trials Study Group. Onceand twice-daily dosing with ros iglitazone im-\nproves glycemic control in patients with ty pe 2 diabetes. Diabetes Care. 2001;24(2):308\u2013315. \n175. Raskin P, Rendell M, Riddle MC, et al. Rosiglitazone Clin ical Trials Study Group. A randomized trialof rosiglitazone thera py in patients \nwith inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001; 24(7):1226\u20131232. G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  72 \n176. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group.  The impact of pioglitazone on gl ycemic-\ncontrol and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12(5):413\u2013423. \n177. G\u00f2mez-Perez FJ, Fanghanel-Salmon G, Antoni o Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexic ans with \ntype 2 diabetes. Diabetes Metab Res Rev. 2002;18(2):127\u2013134. \n178. Scherbaum WA, Goke B; German Pioglitazone Study Group. Meta bolic efficacy and safety of once-daily pioglitazone monotherap y in \npatients with type 2 diabetes: a double-blind, placebo controlled study. Horm Metab Res. 2002;34(10):589\u2013595. \n179. Barnett AH, Grant PJ, Hitman GA, et al, for the Indo-Asian Trial Investigators. Rosiglitazone in type 2 diabetes mellitus:  an evaluation in \nBritish Indo-Asian patients. Di abet Med. 2003;20(5):387-393. \n180. Herz M, Johns D, Reviriego J, et al. A randomized, double blind,placebo-controlled clinical trial of the effects of piogli tazone on glycemic \ncontrol and dislipidemia in oral antihyperglycemic medication- na\u00efve patients with type 2 diabet es mellitus. Clin Ther. 2003;25( 4):1074-\n1095. \n181. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metform in on glycemic control and indicators of insulin \nsensitivity in recently diagnosed patients with type 2 di abetes. J Clin Endocrinol Metab. 2003; 88(4):1637\u20131645. \n182. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti  P; Quartet Study Group. Effi cacy and safety of pioglitazon e versus \nmetformin in patients with type 2 diabetes mellitus: a double blind, randomized trial. J Clin Endocrinol Metab. 2004;89(12):606 8\u20136076. \n183. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term  efficacy and tolerability of add-on pioglitazone therapy to fai ling monotherapy \ncompared with addition of gliclazide or  metformin in patients with type 2 di abetes. Diabetologia. 2005;48(6):1093-104. \n184. Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J. Metabolic effects of pioglitazone in combination with insulin in patients with \ntype 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of  a six-month, randomized, d ouble blind, \nprospective, multicentre, parallel-grou p study. Clin Ther. 2005;27(5):554-567. \n185. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk mark ers by pioglitazone is independent from glycem ic control: \nresults from the pioneer study. J Am Coll Cardiol. 2005; 45(12):1925\u20131931. \n186. Yamanouchi T, Sakai T, Igarashi K, Ichiyanagi K, Watanabe H, Kawasaki T. Compar ison of metabolic effects of pioglitazone, metformin, \nand glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med. 2005;22(8):980\u2013985. \n187. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared wi th dose \nescalation of metformin in type 2 diabetes: the EMPIRE study. Curr Med Res Opin. 2005;21(12):2029\u20132035. \n188. Garber A, Klein E, Bruce S, Sankoh S, Mohideen P. Metformin -glibenclamide versus metformin plus rosiglitazone in patients with type 2 \ndiabetes inadequately controlled on metformin monot herapy. Diabetes Obes Metab. 2006;8(2):156-163. \n189. Majima T, Komatsu Y, Doi K, et al. Safety  and efficacy of low-dose pioglitazone (7.5 mg \u2044day) vs. standard-dose pioglitazone (15 mg \u2044day) \nin Japanese women with type 2 diabetes mellitus. Endocr J. 2006;53(3):325\u2013330. \n190. Perriello G, Pampanelli S, Di Pietro C, Brunetti P, Italian Pioglitazone Study Group. Compar ison of glycaemic control over  1 year with \npioglitazone or gliclazide in patients with Type 2 diabetes. Diabet Med. 2006; 23(3): 246\u2013252. \n191. Umpierrez G, Issa M, Vlajnic A. Glim epiride versus pioglitazone combination ther apy in subjects with type 2 diabetes inade quately con-\ntrolled on metformin monotherapy: results of a randomized  clinical trial. Curr Med Res Opin. 2006;22(4):751\u2013759. \n192. Dargie HJ, Hildebrant, PR, Riegger GAJ, et al. A randomized, placebo controlled trial assessi ng the effects of rosiglitazo ne on echocardi-\nographic \nfunction and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart  failure. J Am \nColl Cardiol. 2007;49(16):1696-1704. \n193. Davidson JA, McMorn SO, Waterhouse BR, Corbitz AR. A 24-week , multicentre, randomized, double-blind, placebo-controlled, p arallel-\ngroup study of the efficacy and tolerability of combination t herapy with rosiglitazone and sulf onylurea in African American and  Hispanic \nAmerican patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther. 2007;29(9):1900-1914. \n194. Hollander P, Yu D, Chou H. Low-dose rosiglitazone in pati ents with insulin-requiring type 2 diabetes. Arch Intern Med. \n2007;167(12):1284-1290. \n195. Hamann A, Garcia-Puig J, Paul G, Donal dson J, Stewart M. Comparison of fixed-dos e rosiglitazone/ metformin combination the rapy with \nsulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controll ed on metformin alone. Exp Cli n Endo-\ncrinol Diabetes. 2008;116(1):6-13. \n196. Rosenstock J, Chou HS, Matthaei S, Seidel DK, Hamann A. Po tential benefits of early addition of rosiglitazone in combination with \nglimepiride in the treatment of type 2 diabet es. Diabetes Obes Metab. 2008;10(10):862-873. \n197. Nissen SE, Nicholls SJ, Wolski K, et  al. PERISCOPE Investigators. Comparison of  pioglitazone vs glimepiride on progression  of coronary \natherosclerosis in patients with type 2 diabetes: the PERIS COPE randomized controlled trial. JAMA. 2008;299(13):1561-1573. \n198. Esposito K, Maiorino M, Di Palo C,  et al. Effects of pioglitazone vs metform in on circulating endothelial microparticles a nd progenitor cells \nin patients with newly diagnosed type 2 diabetes. A randomized Cont rolled trial. Diabetes Obes Metab. 2011 Jan 21. doi: 10.1111 /j.1463-\n1326.2011.01367. \n199. Testa MA, Simonson DC: Health economic  benefits and quality of life during improved glycemic control in patients with type  2 diabetes \nmellitus. JAMA. 1998;280(17):1490-1496 \n200. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients wit h type 2 \ndiabetes mellitus: a one-year, randomized, double- blind assessment of metabolic parameter s and cardiovascular risk factors. Cli n Ther. \n2003; 25(2):472\u2013484. \n201. Feinglos M, Dailey G, Cefalu W, Osei K Tayek J, Canovatchel W. Effect of glycem ic control of the addi tion of 2.5 mg glipiz ide GITS to \nmetformin in patients with T2DM. Diabetes Res Clin Pract. 2005;68(2):167-175. G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  73 \n202. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately \ncontrolled by metformin and a thiazolidinedione: results of a 30- week, randomized, double-blind, placebo-controlled, parallel- group \nstudy. Clin Ther. 2005;27(10):1535\u20131547. \n203. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term t herapy with addition of pioglitazone to met formin \ncompared with the addition of gliclazide to metformin in pati ents with type 2 diabetes: a randomized, comparative study. Diabet es Metab \nRes Rev. 2005;21(2):167-174. \n204. Ristic S, Collober-Maugeais C, Pecher E,  Cressier F. Comparison of nateglinide and gliclazide in combination with metformi n, for treat-\nment of patients with type 2 diabetes mellitus inadequately c ontrolled on maximum doses of metformin alone. Diabet Med. \n2006;23(7):757-762. \n205. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin impr oves gly-\ncemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23(11):1660\u20131665. \n206. Hanefeld M, Bouter KP, Dickin son S, Guitard C. Rapid and short-acting meal time insulin secretion with nateglinide controls  both prandial \nand mean glycemia. Diabetes Care. 2000;23(2):202-207. \n207. Marre M, Van Gaal L, Usadel K-H, Ba ll M, Whatmough I, Guitard C. Nateglinide im proves glycaemic control when added to metf ormin \nmonotherapy: results of a randomized trial with type 2 dia betes patients. Diabetes O bes Metab. 2002;4(3):177-186. \n208. Fonseca V, Grunberger G, Gupta S, Shen S, Foley JE. Addi tion of nateglinide to rosiglitazone monotherapy suppresses mealti me hyper-\nglycemia and improves overall glycemic control. Diabetes Care. 2003;26(6):1685-1690. \n209. Derosa G, Mugellini A, Ciccarelli L, Cr escenzi G, Fogari R. Compar ison of glycaemic control and cardiovascular risk profil e in patients \nwith type 2 diabetes during treatment with either repaglini de or metformin. Diabetes Res Clin Pract. 2003;60(3):161\u2013 169. \n210. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy a nd safety \nstudy. J Clin Pharmacol. 2000;40(1):49\u201357. \n211. Gonzalez-Clemente JM, for the Spanish Nateglinide Study Group:  Improvement of lycemic contro l by nateglinide decreases sys tolic \nblood pressure in drug-na\u00efve patients with type 2 diabetes. Eur J Clin Invest. 2008;38(3):174-179. \n212. Dornan TL, Heller SR, Peck GM, Tattersall RB. Double-blind ev aluation of efficacy and tolerability of metformin in NIDDM. Diabetes \nCare. 1991;14(4):342\u2013344. \n213. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter M etformin \nStudy Group. N Engl J Med. 1995;333(9):541\u2013549. \n214. Del Prato S, Erkelens DW, Leutenegger M. Six-month efficacy of benfluorex vs. placebo or metformin in diet failed type 2 d iabetic pa-\ntients. Acta Diabetol. 2003;40(1):20-27. \n215. Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ. The Me tformin Trial Group. Continuing me tformin when starting insulin i n patients \nwith type 2 diabetes: a double-blind randomized placebo  controlled trial. Diabet Med. 2005;22(5):634\u2013640. \n216. Fujioka K, Grazg RL, Raz I, et al. Efficacy, dose response relationship and safety of one-daily extended-release metformin  in type 2 \ndiabetic patients with inadequate glycemic control despite prior treatment with diet and exercise: results from two double-blin d, placebo-\ncontrolled studies. Diabetes O bes Metab. 2005;7(1):28-39. \n217. Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone \u2044 metformin fixed-dose combination compar ed with uptitrated metformin alone in \ntype 2 diabetes mellitus: a 24-week, multic enter, randomized, double-blind, parallel-group study. Clin Ther. 2005; 27(10):1548\u2013 1561. \n218. Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnso n-Levonas AO, Kaufman KD, Goldstein BJ. The  \neffect of initial therapy with the fixed- dose combination of sitagliptin and metformin compared with metformin monotherapy in p atients \nw\nith type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:644-652 \n G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  74 \n5 Literatur \n \n 1.  Gross JL, Kramer CK, Leitao CB, Hawkins N, Viana LV, Schaan BD, Pinto LC, \nRodrigues TC, Azevedo MJ. Effect of antihyperglycemic agents added to metformin \nand a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011;154(10):672-9 http://www.ncbi.nlm.nih.gov/pubmed/21576535 , DOI: 10.1059/0003-4819-154-10-\n201105170-00007. \n 2.  McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, Dahl M. Second-line \ntherapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011;5(1):e35-e48 http://www.ncbi.nlm.nih.gov/pubmed/22046219 . \n 3.  Carnethon MR, De Chavez PJ, Biggs ML, Lewis CE, Pankow JS, Bertoni AG, Golden \nSH, Liu K, Mukamal KJ, Campbell-Jenkins B, Dyer AR. Association of weight status with mortality in adults with incident diabetes. JAMA 2012;308(6):581-90 http://www.ncbi.nlm.nih.gov/pubmed/22871870 , DOI: 10.1001/jama.2012.9282. \n 4.  Lerch C, Richter B. Kombinationstherapie mit Insulin und oralen Antidiabetika. Z Allg \nMed 2010;6-13, DOI: 10.3238/zfa.2010.0006 . \n 5.  Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, \nMarinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med \n2011;154(9):602-13 http://www.ncbi.nlm.nih.gov/pubmed/21403054 , DOI: \n10.1059/0003-4819-154-9-201105030-00336. \n 6.  Bennett WL, Wilson LM, Bolen S, Maruthur N, Singh S, Chatterjee R, Marinopoulos \nSS, Puhan MA, Ranasinghe P, Nicholson WK, Block L, Odelola O, Dalal DS, \nOgbeche GE, Chandrasekhar A, Hutfless S, Bass EB, Segal JB. Oral Diabetes \nMedications for Adults with Type 2 Diabetes: An Update. Rockville: AHRQ; 2011 \n(Comparative Effectiveness Reviews; 27). Available from: http://www.ncbi.nlm.nih.gov/books/NBK55754/ . \n 7.  Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients \nat HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes \nObes Metab 2012;14(3):228-33 http://www.ncbi.nlm.nih.gov/pubmed/21958121 , DOI: \n10.1111/j.1463-1326.2011.01512.x. \n 8.  Hemmingsen B, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T. \nComparison of metformin and insulin versus insulin alone for type 2 diabetes: \nsystematic review of randomised clinical trials with meta-analyses and trial sequential \nanalyses. BMJ 2012;344:e1771 http://www.ncbi.nlm.nih.gov/pubmed/22517929 . \n 9.  Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-\n4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic \nreview and meta-analysis. BMJ 2012;344:e1369 http://www.ncbi.nlm.nih.gov/pubmed/22411919 . \n 10.  Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in \ntype 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  75 \nDis 2010;20(4):224-35 http://www.ncbi.nlm.nih.gov/pubmed/19515542 , DOI: \n10.1016/j.numecd.2009.03.015. \n 11.  Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like \npeptide-1 receptor agonists on weight loss:  systematic review and meta-analyses of \nrandomised controlled trials. BMJ 2012;344:d7771 \nhttp://www.ncbi.nlm.nih.gov/pubmed/22236411 . \n 12.  Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of \nmetformin treatment and dose on glycemic control. Diabetes Care 2012;35(2):446-54 http://www.ncbi.nlm.nih.gov/pubmed/22275444 , DOI: 10.2337/dc11-1465. \n 13.  Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on \ncardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011;13(3):221-8 \nhttp://www.ncbi.nlm.nih.gov/pubmed/21205121 . \n 14.  The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other \nOutcomes in Dysglycemia. N Engl J Med 2012; \nhttp://www.ncbi.nlm.nih.gov/pubmed/22686416 , DOI: 10.1056/NEJMoa1203858. \n 15.  Gallwitz B, Guzman J, Dotta F, Guerci B, Simo R, Basson BR, Festa A, Kiljanski J, \nSapin H, Trautmann M, Schernthaner G. Exenatide twice daily versus glimepiride for \nprevention of glycaemic deterioration in patients with type 2 diabetes with metformin \nfailure (EUREXA): an open-label, randomised controlled trial. Lancet 2012;379(9833):2270-8 http://www.ncbi.nlm.nih.gov/pubmed/22683137 , DOI: \n10.1016/S0140-6736(12)60479-6. \n 16.  UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with \nsulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837-53 http://www.ncbi.nlm.nih.gov/pubmed/9742976 . \n 17.  UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose \ncontrol with metformin on complications in overweight patients with type 2 diabetes \n(UKPDS 34). Lancet 1998;352(9131):854-65 \nhttp://www.ncbi.nlm.nih.gov/pubmed/9742977 . \n 18.  Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, \nFuruyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract \n1995;28(2):103-17 http://www.ncbi.nlm.nih.gov/pubmed/7587918 . \n 19.  Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial \nintervention and cardiovascular disease in patients with type 2 diabetes. N Engl J \nMed 2003;348(5):383-93 http://www.ncbi.nlm.nih.gov/pubmed/12556541 . \n 20.  Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules \nIK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet \n2005;366(9493):1279-89 http://www.ncbi.nlm.nih.gov/pubmed/16214598 . G\u00fcltigkeit abgelaufen, NVL in \u00dcberpr\u00fcfung.NVL Therapie des Typ-2-Diabetes \nEvidenztabellen \n1. Auflage, Version 1 \n\u00a9  2014  76 \n 21.  Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman \nWC, Genuth S, Ismail-Beigi F, Grimm RH, Jr., Probstfield JL, Simons-Morton DG, \nFriedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59 http://www.ncbi.nlm.nih.gov/pubmed/18539917 . \n 22.  Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper \nM, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, \nTravert F. Intensive blood glucose control and vascular outcomes in patients with \ntype 2 diabetes. N Engl J Med 2008;358(24):2560-72 http://www.ncbi.nlm.nih.gov/pubmed/18539916 . \n 23.  Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, \nMarks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, \nHenderson WG, Huang GD. Glucose control and vascular complications in veterans \nwith type 2 diabetes. N Engl J Med 2009;360(2):129-39 http://www.ncbi.nlm.nih.gov/pubmed/19092145 . \n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}